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ABSTRACT 
 
 
 Human influenza pandemics occur when influenza viruses to which the 
population has little or no immunity emerge and acquire the ability to transmit among 
humans. Since their emergence in 1996, human infections with highly pathogenic avian 
influenza A (H5N1) viruses presented a serious public health challenge. Additionally, 
H5N1 viruses caused significant agricultural and economic losses in the communities it 
has affected. Human infections with these viruses are rare but when they occur, these 
infections are highly fatal. A greater public health concern stems from the rapid evolution 
displayed by these viruses so far, which in turn might result in viruses able to cause 
sustained and widespread human-to-human transmission. 
 
The development of H5N1 vaccines that can induce protective antibody responses 
is the cornerstone of the global efforts to address this pandemic threat. However, it was 
repeatedly shown in clinical trials that (at comparable antigen doses) candidate human 
H5N1 influenza vaccines generally elicit lower immune responses than seasonal human 
influenza vaccines. In addition, the evolution of H5N1 viruses into at least 10 
antigenically distinct clades and multiple subclades suggests that an optimal H5N1 
vaccine should confer cross-reactivity against H5N1 viruses from other clades. Therefore, 
the WHO has recommended the use of adjuvants especially the oil-in-water emulsions 
(such as MF59) in combination with H5N1 split or subunit vaccines. While the ability of 
these adjuvants to generally boost the vaccine-specific antibody titers has been well 
documented, the question of how adjuvants modulate the quality of such responses 
remains largely unanswered.  
 
First, we studied the impact of two adjuvants that are licensed with human 
influenza vaccines, MF59 and alum on the kinetics of developing protective antibody 
responses to subunit H5N1 vaccines in the ferret model. With a single immunization 
regimen, we found that including adjuvants in the vaccine formulation was essential for 
protection against a lethal H5N1 virus challenge. Adjuvanted vaccines provided 
protection against lethality when administered as early as 7 days prior to challenge and 
protection against challenge-associated morbidity when administered 14 days or longer 
prior to challenge. 
 
We also examined the breadth of the antibody responses to adjuvanted vs. 
unadjuvanted H5N1 vaccines. Previous studies have suggested that the oil-in-water 
emulsion adjuvanted vaccines did not only elicit higher antibody titers against 
homologous H5N1 strains, but also against representative isolates of different clades. Our 
data clearly showed that indeed MF59-adjuvanted H5N1 vaccines elicited a 
quantitatively greater H5-specific antibody response than the alum-adjuvanted or the 
unadjuvanted vaccine. However, for the most part, the specificity of these antibodies as 
determined by binding to H5 antigen microarray and competitive ELISA assays was not 
different than induced by alum or vaccine alone. 
 
vi 
 
Finally, we tested the contribution of the cytosolic innate immune sensing 
complex known as the NLRP3 (also known as cryopyrin, CIAS1, or Nalp3) 
inflammasome is in the adjuvant effect of MF59. It was recently shown that activation of 
the NLRP3 inflammasome is essential for the adjuvant effect of alum. Our data clearly 
demonstrated that while the NLRP3 is dispensable for the antibody responses to 
MF59-adjuvanted H5N1 vaccines, ablation of the adapter molecule ASC abrogated these 
responses.  
 
  
vii 
 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION .....................................................................................1 
Influenza A Viruses .........................................................................................................1 
Ecology ........................................................................................................................1 
Structure and Replication .............................................................................................1 
Seasonal Influenza Viruses ..........................................................................................3 
Pandemic Potential of Influenza A Viruses .................................................................3 
Avian Influenza A Viruses; H5N1 Viruses .....................................................................4 
Epidemiology and Genetic Diversity of H5N1 Viruses...............................................4 
Pathogenesis .................................................................................................................6 
Antigenic Structure of H5 HA .....................................................................................6 
The Immune Response to Influenza Viruses ...................................................................7 
The Innate Immune Responses ....................................................................................7 
The Humoral Immune Responses ................................................................................9 
Cytotoxic T-Lymphocytes (CTLs) ............................................................................13 
Immune Correlates of Protection ...............................................................................13 
Influenza Vaccines .........................................................................................................13 
The Challenges of Vaccination against H5N1 ...........................................................13 
Inactivated Virus Vaccines ........................................................................................15 
Live Attenuated Virus Vaccines ................................................................................15 
Universal Target Approaches ....................................................................................16 
Adjuvants for Vaccines against H5N1 Influenza Viruses .............................................16 
Why Are Adjuvants Needed for Influenza Vaccines? ...............................................16 
General Mechanisms of Action of Adjuvants ............................................................17 
Mineral Salts ..............................................................................................................18 
Emulsions ...................................................................................................................18 
MF59 ..........................................................................................................................19 
Scope and Objectives of Dissertation ............................................................................19 
Specific Aim 1 ...........................................................................................................20 
Specific Aim 2 ...........................................................................................................20 
Specific Aim 3 ...........................................................................................................20 
CHAPTER 2. ADJUVANTS ENHANCE THE KINETICS OF PROTECTIVE 
ANTIBODY RESPONSES TO H5N1 INFLUENZA VACCINES .............................21 
Introduction ....................................................................................................................21 
Materials and Methods ...................................................................................................22 
Viruses .......................................................................................................................22 
Immunization and Challenge .....................................................................................23 
Virus Titration ............................................................................................................23 
Serologic Tests ...........................................................................................................23 
Results ............................................................................................................................24 
MF59-Adjuvanted H5N1 Vaccine Provides Fast Protection against Challenge-
Associated Mortality and Morbidity ..........................................................................24 
Kinetics of the Antibody Response to the MF59-Adjuvanted H5N1 Vaccines ........24 
viii 
 
Impact of Alum on H5N1 Vaccine-Mediated Protection Kinetics ............................28 
Discussion ......................................................................................................................28 
CHAPTER 3. ADJUVANTS’ IMPACT ON THE BREADTH OF THE 
ANTIBODY RESPONSES TO SUBUNIT H5N1 INFLUENZA VACCINES ...........34 
Introduction ....................................................................................................................34 
Materials and Methods ...................................................................................................35 
Viruses .......................................................................................................................35 
Mice and Immunization .............................................................................................35 
Hemagglutination Inhibition Assay ...........................................................................35 
Elispot Assay .............................................................................................................35 
Enzyme-Linked Immunosorbent Assay (ELISA) ......................................................36 
Competitive ELISA ...................................................................................................36 
Flow Cytometry .........................................................................................................36 
PCR Amplifications and High-Throughput Pyrosequencing and Analysis of the 
Immunoglobulin Heavy Chain Variable Genes .........................................................37 
H5 Antigen Microarray ..............................................................................................37 
Statistical Analysis .....................................................................................................37 
Results ............................................................................................................................39 
MF59 is Superior to Alum in Priming for Robust H5-Specific Antibody 
Responses ...................................................................................................................39 
MF59 and Alum Enhance the Affinity Maturation of the B-Cell Response to 
H5N1 Vaccine ............................................................................................................39 
Similar Binding Pattern by Adjuvanted and Unadjuvanted H5 Immune 
Serum-Derived IgGs to H5 HA Antigen Microarray.................................................42 
Similar Inhibition Pattern by Adjuvanted and Unadjuvanted H5 Immune Sera by 
H5 Monoclonal Antibodies ........................................................................................42 
Discussion ......................................................................................................................44 
CHAPTER 4. INFLAMMASOME-INDEPENDENT ROLE OF THE 
APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN CONTAINING CARD 
(ASC) IN THE ADJUVANT EFFECT OF MF59 ........................................................47 
Introduction ....................................................................................................................47 
Materials and Methods ...................................................................................................48 
Mice and Immunization .............................................................................................48 
Hemagglutination Inhibition Assay ...........................................................................48 
Elispot Assay .............................................................................................................48 
Enzyme-Linked Immunosorbent Assay (ELISA) ......................................................49 
Flow Cytometry .........................................................................................................49 
Generation and Analysis of Bone Marrow-Derived Dendritic Cells .........................49 
Statistical Analysis .....................................................................................................49 
Results ............................................................................................................................50 
The Humoral Immune Response to MF59-Adjuvanted Vaccines Requires ASC 
but Not NLRP3 or Caspase-1 ....................................................................................50 
ASC Is Required for Germinal Center B-Cell Formation after Immunization with 
MF59-Adjuvanted Vaccines ......................................................................................50 
ix 
 
ASC Is Required for Robust Antigen-Specific Recall B-Cell Responses .................53 
ASC Expression in Dendritic Cells Is Required for Adequate Production of 
Inflammatory Cytokines ............................................................................................57 
Discussion ......................................................................................................................57 
CHAPTER 5. GENERAL CONCLUSIONS, LIMITATIONS AND FUTURE 
DIRECTIONS ..................................................................................................................60 
Adjuvants Enhance the Kinetics of Protective Antibody Responses to H5N1 
Influenza Vaccines .........................................................................................................61 
Implications and Limitations .....................................................................................62 
Future Directions .......................................................................................................62 
Adjuvants’ Impact on the Breadth of the Antibody Responses to Subunit H5N1 
Influenza Vaccines .........................................................................................................63 
Implications and Limitations .....................................................................................63 
Future Directions .......................................................................................................64 
Inflammasome-Independent Role of the Apoptosis-Associated Speck-Like Protein 
Containing CARD (ASC) in the Adjuvant Effect of MF59 ..........................................65 
Implications and Limitations .....................................................................................65 
Future Directions .......................................................................................................66 
LIST OF REFERENCES ................................................................................................67 
APPENDIX A. IMPACT OF PRIOR SEASONAL INFLUENZA 
VACCINATION AND INFECTION ON PANDEMIC A (H1N1) INFLUENZA 
VIRUS REPLICATION IN FERRETS .........................................................................73 
APPENDIX B. CONTEMPORARY SEASONAL INFLUENZA A (H1N1) 
VIRUS INFECTION PRIMES FOR A MORE ROBUST RESPONSE TO 
SPLIT INACTIVATED PANDEMIC INFLUENZA A (H1N1) VIRUS 
VACCINATION IN FERRETS......................................................................................74 
VITA..................................................................................................................................75 
 
  
x 
 
LIST OF TABLES 
 
Table 1-1. Adjuvants that were shown to significantly boost influenza vaccines in 
humans. .........................................................................................................17 
Table 2-1. Effect of the different vaccination regimen on survival and clinical signs 
of infection in ferrets challenged with A/Vietnam/1203/04 (H5N1) 
influenza virus. ..............................................................................................25 
Table 2-2. Effect of different vaccination regimen on A/Vietnam/1203/04 (H5N1) 
influenza virus replication in the upper respiratory tract of ferrets. .............27 
Table 2-3. Impact of Alum-adjuvanted H5N1 SU vaccine on survival and clinical 
signs of infection in ferrets challenged with A/Vietnam/1203/04 (H5N1) 
influenza virus. ..............................................................................................29 
Table 2-4. Serological titers and viral load in ferrets immunized with Alum-
adjuvanted H5N1 SU vaccine and challenged with A/Vietnam/1203/04 
(H5N1) influenza virus. ................................................................................30 
Table 3-1. List of peptide sequences that are used to coat H5 microarray chips. ..........38 
 
  
xi 
 
LIST OF FIGURES 
 
Figure 1-1. Structure of influenza A viruses. ....................................................................2 
Figure 1-2. Virulence factors and phylogenetic analysis of H5N1 influenza A 
viruses. ............................................................................................................5 
Figure 1-3. The antigenic structure of the H5 HA from A/Vietnam/1203/2004 
(H5N1). ...........................................................................................................8 
Figure 1-4. Innate immune pathways involved in recognition of viruses. ......................10 
Figure 1-5. Mechanisms of antibody mediated immunity against influenza viruses. .....11 
Figure 1-6. The estimated time line for the current influenza vaccine manufacturing 
process...........................................................................................................14 
Figure 2-1. Weight loss in the unadjuvanted and MF59-adjuvanted groups 5 days 
post challenge with A/Vietnam/1203/04 (H5N1) virus. ...............................26 
Figure 3-1. Superior priming with MF59-adjuvanted H5N1 vaccines in comparison 
to the alum-adjuvant or the unadjuvanted formulations. ..............................40 
Figure 3-2. Increased affinity maturation of the B-cell responses mediated by alum- 
and MF59-adjuvanted H5N1 vaccines. .........................................................41 
Figure 3-3. Similar pattern of binding of immune sera to H5 antigen microarrays. .......43 
Figure 3-4. Equivalent inhibition of adjuvanted and unadjuvanted H5 immune sera 
by H5 human monoclonal antibodies. ..........................................................45 
Figure 4-1. Defective humoral immune response to MF59-adjuvanted H5N1 
vaccines in ASC knockout mice. ..................................................................51 
Figure 4-2. Anti-H5 antibody responses in ASC-/- are not generally defective. ..............52 
Figure 4-3. Defective germinal center B-cell development in ASC-/- after 
immunization with MF59-adjuvanted H5N1 subvirion vaccine. .................54 
Figure 4-4. Poor H5-specific antibody recall responses in immunized ASC-/- mice. ......56 
Figure 4-5. Defective inflammatory responses in ASC-/- bone marrow-derived 
dendritic cells (BMDCs) to MF59. ...............................................................58 
 
  
xii 
 
LIST OF ABBREVIATIONS 
 
 
AFCs   Antibody Forming Cells 
AP-1 Activator Protein 1 
APCs   Antigen Presenting Cells 
ASC Apoptosis-Associated Speck-Like Protein Containing a CARD 
BMDCs  Bone Marrow Derived Dendritic Cells 
CARD Caspase Activation and Recruitment Domain 
CDC US Centers for Disease Control and Prevention 
CFA   Complete Freund’s Adjuvant 
CTLs   Cytotoxic T-Lymphocytes 
DAMPs Danger Associated Molecular Patterns 
DCs   Dendritic Cells 
dsRNA Double-Stranded RNA 
ELISA   Enzyme-Linked Immunosorbent Assay 
GCs   Germinal Center B-Cells 
H1N1pdm 2009 Pandemic Influenza A Virus (H1N1) 
HA Hemagglutinin 
HI   Hemagglutination Inhibition 
HPAI   Highly Pathogenic Avian Influenza  
IAVs   Influenza A Viruses 
IFN Interferon 
IL Interleukin  
IPAF ICE-Protease Activating Factor 
ISRE Interferon-Sensitive Response Element  
LAIVs   Live Attenuated Influenza Virus Vaccines 
LPS Lipopolysaccharides 
M1 Matrix Protein 1 
M2 Matrix Protein 2 
M2e   M2 Protein Ectodomain  
mAbs   Monoclonal Antibodies 
MAP Mitogen-Activated Protein 
MDA5 Melanoma Differentiation-Associated Gene 5 
MyD88 Myeloid Differentiation Primary Response Protein 88 
NA Neuraminidase 
NALP1 NACHT-LRR-PYD-Containing Protein-1 
NEP Nuclear Export Protein 
NF-kB Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B cells 
NLRP3 NOD-Like Receptor Family, Pryin Domain Containing 3 
NLRs NOD-Like Receptors 
NOD Nucleotide-Binding Oligomerization Domain-Containing Protein 
NP Nucleoprotein 
NS1 Non Structural Protein 1 
NS2 Non Structural Protein 2 
PA Polymerase Acidic 
xiii 
 
PAMPs Pathogen Associated Molecular Patterns  
PB1 Polymerase Basic 1 
PB2 Polymerase Basic 2 
PBS   Phosphate-Buffered Saline 
PCs   Plasma Cells 
PRRs Pattern Recognition Receptors 
RBCs   Red Blood Cells 
RIG-I Retinoic Acid Inducible Gene I 
RLRs RIG-Like Receptors 
RNA Ribonucleic Acid 
RNP Ribonucleoprotein 
ssRNA Single-Stranded RNA 
TIV    Trivalent Inactivated Influenza Vaccine 
TLRs Toll-Like Receptors  
TRIF Toll/IL-1 Domain-Containing Adaptor-Inducing IFN-Beta 
WHO   World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1.    INTRODUCTION1 
 
 
Influenza A Viruses 
 
 
Ecology 
 
Influenza viruses belong to the Orthomyxoviridae family and are antigenically 
classified into three different classes; A, B and C (1). Aquatic birds are considered the 
primary reservoir for influenza A viruses (2). Other animal hosts from which influenza A 
viruses were isolated includes humans, pigs, birds, horses, whales, seals and mink (2). 
Humans get transiently infected with a limited number of influenza A viruses subtypes. 
The site of viral replication in aquatic birds is in the cells lining the gastro-intestinal tract 
(2). In humans, the virus replicates primarily in the respiratory tract. It is not uncommon 
for influenza A viruses to cross the interspecies barrier which, as it will be discussed 
below, can lead to serious consequences. 
 
 
Structure and Replication 
 
Influenza A viruses are enveloped, negative sense, single stranded RNA viruses 
with a segmented genome (1). The eight segments of influenza A viral genome code for 
up to11 proteins. As shown in Fig. 1-1, three of these proteins are expressed on virus 
surface; first, the hemagglutinin (HA), which is a homotrimeric glycoprotein that is 
responsible for the initial virus attachment to host epithelial cells and the subsequent 
virus entry (3). HA also mediates virus fusion with the endosomal membrane, which in 
turn allows for the virus replication machinery to be transported into the cytosol (3). 
Second, the neuraminidase (NA), which is a homotetramer that cleaves budding viral 
particles from the host infected cells (4). Influenza A viruses are further classified based 
on the antigenicity of their surface HA and NA molecules. To date there are 16 HA 
subtypes (H1-H16) and 9 NA subtypes (N1-N9) identified (5). The third surface 
glycoprotein is the matrix protein 2 (M2), produced as a splice variant of the matrix gene 
and acts as an ion channel (6) that is responsible for acidifying the viral core, an essential 
step during viral replication (1). While HA is the major target of virus neutralizing 
antibodies, NA and M2 are the major targets of the most commonly used anti-influenza 
antiviral drugs. Matrix protein 1 or M1 binds to the cytosolic domains of HA, NA and 
M2 forming a septum between the viral membrane and viral internal proteins (1). Four 
internal viral proteins, the nucleoprotein (NP), the RNA polymerase basic 1 and 2 (PB1 
and PB2) and the RNA polymerase acidic (PA), form the ribonucleoprotein (RNP) 
complex which represents the viral replication apparatus (1).  
                                                 
 
1 Parts of this chapter were adapted with permission. A. H. Ellebedy, R. J. Webby,   
Vaccine 27 Suppl 4, D65 (Nov 5, 2009) (48) and S. A. Valkenburg et al., Microbes 
Infect 13(5):489-501 (Feb 1, 2011) (45). 
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particle leading to their release from infected cells (10). Finally, for the budding virus 
particles to be infective, proteolytic cleavage of the HA by host proteases must occur 
(10). This step is a major determinant of virus tropism. 
 
 
Seasonal Influenza Viruses 
 
In the USA, seasonal influenza viruses cause an annual epidemic that usually lasts 
from the month of November to late April or May with the peak number of infections 
occurring in February (11). The most affected age populations in terms of infection rate 
and severity are young children (< 2 years old) and the elderly (> 65 years old) (11). This 
is mostly due to the general weakness of the immune system associated with these age 
groups as well as the lack of preexisting immunity in the young children. Other risk 
groups include individuals with chronic medical conditions and immunocompromised 
patients. Annually, seasonal influenza viruses are responsible for approximately 36,000 
deaths in the US alone (11).  
 
 In the last three decades, three different subtypes of seasonal influenza viruses 
have circulated in the human population; two influenza A viruses with H1N1 and H3N2 
subtypes and influenza B viruses (12). Annual vaccination programs have been 
developed and are effective in reducing the incidence of seasonal influenza-associated 
complications (11). 
 
 The incubation period after seasonal influenza virus infection ranges from one to 
four days (11). Typically, it is characterized by mild respiratory symptoms including 
fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis (11). 
The majority of influenza infections resolve within a week (11). However, influenza virus 
infections can cause primary influenza viral pneumonia; exacerbate underlying medical 
conditions (e.g., pulmonary or cardiac disease); lead to secondary bacterial pneumonia, 
sinusitis, or otitis media; or contribute to coinfections with other viral or bacterial 
pathogens (11).  
 
 
Pandemic Potential of Influenza A Viruses 
 
In order for any influenza virus to cause a pandemic, two conditions must be met; 
1) the majority of the human population has to be immunologically naïve to that virus 
and 2) the virus must efficiently transmit between humans. The emergence of such 
viruses can occur by genetic reassortment of a human influenza virus with a non-human 
virus leading to a reassortant virus with a novel HA and internal genes that allow it to 
replicate efficiently in the human host (13). A pandemic influenza virus can also be 
directly introduced to the human population via interspecies transmission (13). These two 
mechanisms are not mutually exclusive and a combination of the two processes usually 
leads to the genesis of a pandemic virus. During the twentieth century, three influenza 
pandemics occurred (14). The first one was the 1918 Spanish influenza. The causative 
virus was an avian H1N1 virus and the number of people died as a consequence of this 
4 
 
pandemic is estimated to be 50 million (15). The virus infection was not systemic and 
secondary bacterial infection was the leading cause of death (15).  Recently, the H1N1 
virus was recreated using reverse genetics and studies on rodents and non-human 
primates revealed an aberrantly intense innate immune response associated with virus 
infection (15). This fact might explain the fact that young adults were the most affected 
age group. 
 
In 1957, an H2N2 influenza virus caused the second influenza pandemic that is 
also known as the Asian influenza (16). The virus emerged in Sothern China and the 
number of deaths within the US is estimated to be 70,000 (16). The virus resulted from a 
genetic reassortment event with the HA, NA and PB1 genes coming from an avian 
influenza virus while the rest of genes being contributed by a human virus (16). Unlike 
the 1918 pandemic, secondary bacterial infection was not the major cause of death. 
 
The last pandemic of the twentieth century was the Hong Kong influenza. The 
virus emerged in 1968 and has been circulating ever since (16). The pandemic caused 
34,000 deaths in the US (16). It is speculated that preexisting immunity against the N2 
contributed to the decreased mortality (16). 
 
In April of 2009, the US Centers for Disease Control and Prevention (CDC) 
reported two cases of a novel H1N1 influenza virus in children in the southern United 
States (17). It was retrospectively shown that these cases represented the continued 
spread of this virus, subsequently labeled pandemic A (H1N1) 2009 (H1N1pdm), from an 
ongoing outbreak in Mexico (18). The virus was quickly sequenced and shown to be a 
novel reassortant between lineages of influenza viruses known to circulate widely in 
swine (19). Within a matter of weeks the virus had spread to a number of other 
continents, signaling the beginning of the first influenza pandemic of the 21st century. 
 
 
Avian Influenza A Viruses; H5N1 Viruses 
 
 
Epidemiology and Genetic Diversity of H5N1 Viruses 
 
 The first identification of a highly pathogenic H5N1 virus was in 1996 and it was 
from a goose in the Guangdong province of China (20). Since then related viruses have 
spread on a global scale with confirmed human infections in more than 15 countries (20). 
As would have been predicted for an influenza virus, H5N1 influenza viruses have 
evolved into a number of distinct lineages (20). As shown in Fig. 1-2, phylogenic 
analysis of the HA protein alone has shown that there are at least 10 distinct clades of 
H5N1 viruses (21). Many of these clades have only been found in avian species in China 
and the extent to which they circulate is unknown (21). If one considers the clinically 
significant clades (i.e., those associated with human infections) then this list can be 
reduced to 6 clades/subclades; 0, 1, 2.1, 2.2, 2.3 and 7 (21). As such, and without any 
way of predicating which of the clades have any potential for human adaptation, much  
importance has been placed on increasing the cross reactivity of H5N1 vaccines. 
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Pathogenesis 
 
 Among the different avian influenza A viruses that have crossed the interspecies 
barrier and infected humans, the highly pathogenic H5N1 viruses were the most severe in 
terms infection associated morbidity and mortality (22). In Hong Kong in 1997, six out of 
the eighteen individuals infected with H5N1 died (23). There is no clear evidence that 
human-to-human transmission was established (23). The H5N1 viruses caused the 
outbreak were believed to be permanently eradicated by culling all the poultry in the 
Hong Kong markets (23). In 2003, additional human infections caused by H5N1 viruses 
were reported in Hong Kong (23). To date, the mortality rate among humans infected 
with avian H5N1 viruses is estimated to be 60% (23). Genetic analyses performed on 
H5N1 viruses isolated from confirmed human cases did not reveal any genetic 
reassortment between these viruses and human or swine viruses (24). However, 
coinfections experiments have revealed that the potential of emergence of such 
reassortants is viable (25). The role of the host genetic component in the susceptibility to 
infection or the severity of infection associated morbidity was suggested but not 
confirmed (21).  
 
 In general, the incubation period in patients infected with H5N1 viruses ranges 
from two to five days (21). Typically patients present with the regular influenza 
respiratory symptoms. However, gastrointestinal symptoms including diarrhea have also 
been reported (21). Pneumonia, acute respiratory distress and multi organ failure are the 
characteristic symptoms of severe cases and unless intervention with antiviral drugs like 
oseltamivir starts, those patients likely succumb to infection (21). Unlike the pattern with 
seasonal influenza viruses, young adults (10-19 years old) are the most affected age 
population in terms of mortality (26). Autopsies from fatal cases have revealed a massive 
alveolar damage with evidence of heavy involvement of macrophages and neutrophils. In 
addition, high levels of proinflammatory cytokines were detected in the serum (26). 
These findings led to the hypothesis that H5N1 virus associated mortality is mediated by 
the massive innate immune response or “the cytokine storm” (27). It is interesting to note 
that studies with the recreated 1918 H1N1 virus in non-human primates have shown 
similar findings (26). Several of the viral proteins have been associated with the increased 
pathogenicity of these viruses (Fig. 1-2), most notably the HA. The presence of multiple 
basic amino acids at the cleavage site between the HA1 and HA2 subunits allows for the 
ubiquitous activation of the virus particles, which in turn result in enhanced virus 
dissemination and systemic infection (8). 
 
 
Antigenic Structure of H5 HA 
 
The HA structure was solved over 25 years ago and showed the functional protein 
being a homotrimer consisting of a stalk and globular head (28). Stevens et al. have 
resolved the crystal structure of HA from A/Vietnam/1203/2004 (H5N1), an isolate from 
a fatal human infection (29). Although there are minor differences in the structure of HA 
of different subtypes, like the H3 protein, the major antigenic sites of H5 HA cluster in 
and around the receptor binding domain on the globular head (Fig. 1-3) (29). Generally, 
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escape mutants of H5 HAs can be clustered into three hot spots (29); 1) the 140 loop (an 
exposed loop in the HA1 subunit extending from amino acid 140 to 145), 2) HA1 
residues 156 and 157 and 3) HA1 129 to 133 (29).  
 
 
The Immune Response to Influenza Viruses 
 
Influenza A virus infection in humans is acute and the clearance of the virus is 
mediated by several parts of the immune system. Initially, influenza infection triggers a 
robust innate immune response in the form of the secretion of several cytokines and the 
massive influx of inflammatory immune cells such as neutrophils into the respiratory 
tract (7). The early clinical symptoms associated with influenza infection are caused by 
the innate immune responses. These early responses are essential not only for limiting 
virus replication but also for priming the virus specific B- and T-cell responses. On the 
other hand, influenza viruses have developed several evasion strategies such as encoding 
for the NS1 protein which, by sequestering viral RNA, blocks the triggering of the host 
interferon (IFN α/β) response (7). 
 
 
The Innate Immune Responses 
 
 Our knowledge of the contribution of the innate immune system to the overall 
immune response to pathogens and vaccination has expanded over the last decade (30-
32). Recognition of conserved motifs that are associated with microbial infection is the 
initial signal for the generation of an appropriate innate and adaptive immune response 
(30-32). These motifs can be either derived from the invading microbes and thus called 
pathogen associated molecular patterns (PAMPs) or they can be endogenous danger 
signals caused by the infection (danger associated molecular patterns or DAMPs). The 
host cell sensors that evolved to recognize these PAMPs and DAMPs are known as the 
pattern recognition receptors or PRRs. Infection by influenza viruses can be detected by 
three major families of PRRs that were recently identified; the toll-like receptors (TLRs), 
the NOD-like receptors (NLRs) and the RIG-like receptors (RLRs) (30). 
  
 
The Toll-Like Receptors (TLRs). To date, there are eleven TLRs (TLRs1-11) 
that have been characterized in mice (33). These receptors recognize a variety of ligands 
that are mostly microbial derived. TLRs mediate host innate immune responses by 
inducing the secretion of several proinflammatory cytokines through the activation of 
transcriptional factors such as NF-κB, AP-1, ISRE-3 and ISRE-7 (33). TLR3 and TLR7 
recognize double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA), 
respectively (30). Therefore, both of these receptors were the most plausible candidates 
as receptors that detect influenza viruses (30). As for TLR3, studies with TLR3-/- mice 
and mice that are genetically deficient in TLR3 adapter molecule Toll/IL-1 domain-
containing adaptor-inducing IFN-beta (TRIF) have revealed that the adaptive immune 
responses to influenza viruses were intact (34). Type 1 interferon (IFN) response to 
influenza virus was, however, dependent on TLR7 signalling (35). 
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With the exception of TLR3 and a TRIF mediated arm of TLR4 signaling, all TLRs 
mediate their downstream signalling through an adapter molecule known as the myeloid 
differentiation primary response (MyD) 88 or MyD88. Similar to the findings with TLR7 
signalling, IFN response to influenza viruses was also impaired in MyD88-/- mice (Fig. 1-
4)  (33). 
 
 
The NOD-Like Receptors (NLRs). NLRs were recently discovered as 
intracellular sensors that recognize pathogen-associated molecular patterns (PAMPs) as 
well as DAMPs (36). The prototypic members of this family, NOD1 and NOD2, 
recognize two distinct derivatives of bacterial peptidoglycans and mediate the subsequent 
cellular inflammatory response (36). There is a growing list of proteins that are being 
identified as members of the NLRs family (36). It is becoming increasingly clear that 
NLRs are essential components of the innate immune system not only in respect to the 
immunity to microbial pathogens but also to the pathogenesis of autoimmune diseases 
(36). Whereas NOD1 and NOD2 stimulation leads to activation of NF-κB and MAP 
kinases, other NLR proteins such as Ipaf, Nalp1, and NLRP3 mediate their actions 
through the activation of inflammatory caspases such as caspases 1 (36). Caspase-1, 
produced as a zymogen, is recruited to large multiprotein complexes known as 
“inflammasomes” through homotypic interactions with the adapter molecule ASC (36). 
ASC bridges the association of caspase-1 to NLR proteins such as Nalp1 and NLRP3 in 
the inflammasomes leading to the activation of caspase-1 and the subsequent activation 
and secretion of the proinflammatory cytokines IL-1β and IL-18 (32). As for influenza 
infection, there are several reports that link increased susceptibility to influenza infection 
in mice that are deficient in NLRP3 (37). Thomas et al. showed that influenza RNA is 
detected by NLRP3 and the increased susceptibility was linked to the impaired wound 
healing in NLRP3-/- mice (37).  
 
 
The RIG-Like Receptors (RLRs). RIG-I and MDA5, the prototypes of this 
family of receptors, were identified as cytosolic sensors of poly (I:C), a synthetic 
analogue of viral dsRNA (30). Their stimulation ultimately leads to type 1 IFN 
production through the activation of NF-κB, IRF3 and IRF7 transcription factors (30). 
RIG-I was shown to detect influenza virus RNA and that genetic ablation of RIG-I 
caused increased susceptibility to influenza virus infection (30). 
 
 
The Humoral Immune Responses 
 
One of the most striking features of influenza virus infection is the speed with 
which the virus replicates once it is established in the respiratory epithelium. Preformed 
virus-specific antibodies in the serum or, preferably, on the airway mucosal surface can 
block viral entry and the subsequent establishment of infection (38). As a result, all 
licensed inactivated influenza vaccines to date are designed to generate an antibody 
response against the major virus surface molecules, HA and NA (39). A single infection 
with any strain of influenza viruses elicits lifelong antibody-mediated protection 
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Other viral surface glycoproteins that are also targeted by the antibody response 
are the NA and the matrix (M2) proteins. While I am focusing below on the challenges 
and recent advances in generating protective antibody responses to each of these viral 
targets, it is important to note that antibodies targeting some of the internal viral proteins 
such as the NP are also generated in the course of viral infection (40). However, the 
protective potential of such antibodies remains to be fully elucidated. 
 
 
 The Hemagglutinin (HA). As mentioned earlier, HA is the viral glycoprotein 
that mediates virus binding to lung epithelial cells leading to virus entry via receptor-
mediated endocytosis. In addition, HA also mediates virus fusion with endosomal 
membrane, releasing viral genomic materials into the cytosol (41). This “invasion” role 
makes HA the primary target of protective antibodies generated by the host after 
infection or induced by influenza vaccines. Such antibodies, if present to sufficiently high 
titers, can neutralize the virus, i.e. completely prevent viral binding and invasion of 
airway epithelial cells achieving a “sterilizing immunity”. Although there are several  
defined neutralizing antibody recognition sites the HA globular head and antibodies 
targeting one or more of these sites can efficiently neutralize virus infectivity, antigenic 
variation at all sites thwarts the development of long-term, protective influenza vaccines 
(38, 39). Thus, the challenge of eliciting broadly protective anti-HA antibodies is two-
fold; first the ability of such antibodies to cross-react with different HA subtypes and 
second, the ability to cross-react with escape variants of the original HA that the 
antibodies were raised against. Some have suggested that such broad specificities are 
unlikely to exist in principle, or repeated infection would have selected for them. 
However, recent studies have reported antibodies targeting the HA stem region that have 
broad neutralization potential across many subtypes (42). Additionally, the conservation 
of this region among different HA subtypes indicates certain structural restrictions that 
could limit antigenic escape (42). Nevertheless, the immunogenicity and protective 
potential of antibodies targeting the HA stem remain to be fully elucidated. 
 
 
The Neuraminidase (NA). NA-specific antibodies are believed to interfere with 
the virus replication cycle, causing an overall “yield reduction” of virus infection (38, 
39). Unlike anti-HA antibodies, NA-specific antibodies do not block infection initiation 
and so are not sterilizing, but can significantly reduce morbidity and mortality (38, 39). 
Similar to HA, NA exhibits a high degree of variability in terms of antigenicity in 
response to immune pressure rendering anti-NA- mediated protection rather inconsistent 
(38, 39). However, it was shown that antibodies elicited by human NA1 can partially 
protect against H5N1 infection (43). 
 
 
 The Matrix Protein 2 Ectodomain (M2e). A third viral trans-membrane protein 
antibody target is the matrix protein 2 (M2). Early studies in mice showed that anti-M2 
antibodies provided partial protection (38). These results fuelled speculation that M2 
might be the long sought target of a universal influenza vaccine, since, in comparison to 
HA and NA molecules, M2 proteins are highly conserved among different influenza 
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subtypes (38). However, disappointingly, the anti-M2- mediated protection shown in 
mice has not been as dramatic in other, more relevant animal models (44).  
 
 
Cytotoxic T-Lymphocytes (CTLs) 
 
 CTLs are essential for effective clearance of influenza virus infection (45). There 
are two key mechanisms via which CTLs help in controlling influenza virus infection. 
The first one is by direct killing of virus-infected cells. The second mechanism is through 
the production of various proinflammatory cytokines. In addition, the generation of virus 
specific memory CTLs significantly enhances virus clearance upon reexposure (45). The 
majority of CTL epitopes are derived from internal virus proteins such as NP and PB1 
(45). These proteins are relatively conserved in comparison to HA, the main target of 
B-cell responses. Therefore, CTLs are important for generating a cross protective 
anti-influenza immune responses (46). 
 
 
Immune Correlates of Protection 
 
 The immunogenicity of H5N1, and other influenza subtypes, virus vaccine is 
typically tested by the hemagglutination inhibition (HI) assay. For H5N1, horse red blood 
cells (RBCs) are used instead of the traditionally used turkey or chicken RBCs to enhance 
assay sensitivity (47). In general, the sensitivity and specificity of this assay is poor. 
Virus microneutralization (MN) assay is another assay that quantitatively measures the 
levels of neutralizing anti-HA antibodies and it is believed to be more sensitive and more 
functional than HI assay (47). HI titers of 40 or higher are generally considered protective 
assuming that the higher the HI or MN titers the higher the probability of protection (47). 
The enzyme-linked immunosorbent assay or ELISA has also been described to determine 
the levels of anti-HA antibodies (47). In ELISA, however, all (neutralizing and non-
neutralizing) antibodies that bind to the H5 HA are measured. Although ELISA is rapid 
and more sensitive than HI and MN, there is no information regarding the correlation 
between antibody levels and protection. Moreover, the use of whole virus preparations 
instead of purified HA as a coating antigens adds antibodies that target the internal 
protein such as anti-nucleoprotein antibodies to the equation. The clinical implications of 
non-neutralizing antibodies are not fully understood (47). Although these antibodies are 
more likely to be cross reactive among different HA subtypes, the mechanism(s) through 
which they may be contributing in viral clearance is not well studied. 
 
 
Influenza Vaccines 
 
 
The Challenges of Vaccination against H5N1 
 
One of the main challenges facing influenza vaccination in general is the reliance 
of the production system on embryonated chickens eggs and the length of time between 
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Inactivated Virus Vaccines 
 
 Most of the currently licensed influenza vaccines are in the form of inactivated 
antigen preparations. As stated above, all vaccines work primarily through the generation 
of antibodies to HA. As such, they are potent, but prone to antigenic changes such as 
would be expected with the emergence of a new strain in a population. Clinical studies 
have shown that inactivated vaccines have an efficacy, measured by reducing 
serologically confirmed influenza illnesses, of 70% in the age group between 14-60 years 
(49). The efficacy is reduced with both infants and the elderly (50). The first of the 
inactivated vaccine formulation is whole virion, the experimental use of which dates back 
to 1940s. The second is split virion which is derived by disrupting whole virus particles 
with disinfectants and finally, the subunit form, which is prepared by enriching for the 
viral surface glycoproteins HA and neuraminidase (NA) following disruption of viral 
particles. Although arguably more immunogenic, the reactogenicity associated with 
inactivated whole virus vaccine preparations, particularly in infants and children drove 
the development of the split vaccine technology back in the 1960s (51). Split and subunit 
vaccines have subsequently proven to be safe and have been delivered to millions of 
people (52). Unfortunately the relatively poor immunogenicity of split vaccines means 
that at least two doses of vaccine must be provided to generate protective immune 
responses in naïve individuals (53). In the event of a release of a novel and virulent strain 
of influenza, a two dose schedule for vaccination poses logistical and temporal issues. 
 
 
Live Attenuated Virus Vaccines 
 
Unlike inactivated vaccines, live attenuated influenza virus vaccines (LAIVs) are 
administered by intranasal inoculation of replication competent virus. In these vaccine 
viruses, the HA and NA of the target strain is introduced into a backbone of an 
attenuated, cold-adapted virus (54). Cold-adapted influenza viruses are attenuated by 
adapting the viruses to grow at 25ºC (54). The first adapted influenza A virus (commonly 
referred to as the master strain) is A/Ann Arbor/6/60-H2N2 (54). The resulting vaccine 
virus has the antigenic phenotype of the target strain but the attenuated phenotype of the 
master strain.  
 
The perceived advantages of the LAIV approach is that both a local immune 
neutralizing antibody and a cell mediated response can theoretically be generated. Cell 
mediated immunity is an attractive goal for influenza vaccines due to the fact that such 
immunity targets the more conserved viral proteins (46). In an ideal world, such 
immunity would protect across a range of different virus strains. In practice, in the few 
side by side comparisons of LAIV and inactivated vaccines in a seasonal influenza 
setting, the theoretical advantage of a broadened immune response is only seen in the 
younger cohorts (55). This is hypothesized to be due to the over attenuation of the viruses 
in an immunologically primed population. Within the context of a release of a novel 
strain, however, the population will essentially be naïve and LAIV could have an 
important role to play in terms of corresponding vaccine strategies. 
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Despite some advantages, LAIV do suffer from some of the same issues as do 
their inactivated counterparts. LAIV will also likely require two doses to elicit optimal 
immune responses and their generation time is not substantially different from inactivated 
vaccines.  LAIV also have some unique drawbacks in that it is possible not all HA and 
NA combinations will form viable viruses on the attenuated backbone, the vaccine virus 
must be able to infect the human upper respiratory tract (potentially an issue for avian 
strains), and potential safety risks of administering a live virus into a population before 
the target strain is widespread. 
 
 
Universal Target Approaches 
 
 Due to the inherent variation of the influenza HA, a continuous quest of influenza 
immunologists has been to design influenza vaccines based on more conserved viral 
epitopes. One of the most studied and developed of these “universal target” antigen 
vaccines are those that target the extracellular portion of the M2 protein (M2e) (38).The 
M2 protein is a transmembrane ion channel and studies have shown that in appropriate 
configurations and in certain models, antibodies to the M2e domain can be protective; 
virtually no M2e antibodies are produced after natural infection.  
 
M2e is not the only conserved epitope between influenza viruses and a number of 
other proteins have been targeted. These include nucleoprotein and polymerase proteins 
through T cell mediated approaches and also more conserved domains of HA (56). The 
immunogenicity of this part of the HA molecule and its protective potential is promising 
(42). 
 
 
Adjuvants for Vaccines against H5N1 Influenza Viruses 
 
 
Why Are Adjuvants Needed for Influenza Vaccines? 
 
 The poor immunogenicity of split or subunit influenza vaccines is a major 
challenge for the rapid response to an emerging virus. The impact is twofold, first higher 
quantities of antigen are needed per dose to elicit a protective immune response. Second, 
two doses will likely be needed for vaccine recipients to attain these protective responses. 
The use of adjuvants to overcome poor immunogenicity and for antigen sparing is not 
new to vaccinology, indeed, adjuvants such as alum salts for several human vaccines 
started several decades ago (Table 1-1) (26, 57). In addition to their ability to enhance 
vaccine immunogenicity, adjuvants such as the oil-in-water emulsion adjuvant MF59 
have been shown to expand the breadth of an immune response to influenza vaccines (58, 
59).  MF59 induced the generation of higher serum antibody titers as well as more cross 
reactive responses when administered with split or subunit H5N1 vaccines (58, 59). 
Although these vaccines are unlikely to protect across subtypes, they do appear to be 
more cross reactive across the variations within a subtype.  
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Table 1-1. Adjuvants that were shown to significantly boost influenza vaccines in 
humans.  
 
Adjuvant Type Mechanism of action Licensed 
Aluminum salts or alum Mineral salts Depot NLRP3 inflammasome Yes 
MF59 and AS03 Oil-in-water emulsion 
Unknown 
tissue inflammation Yes 
Cholera toxin (CT) and 
E.coli heat labile 
enterotoxin 
Microbial 
derived 
PRRs-independent 
immune potentiation No 
CpG Microbial derived Stimulation of TLR9 No 
Muramyl tripeptide Microbial derived Stimulation of TLR2 No 
IL-2 Cytokine Direct stimulation of the immune response No 
 
Adapted from R. L. Atmar, W. A. Keitel, Curr Top Microbiol Immunol 333, 323 (2009) 
(60). 
 
 
General Mechanisms of Action of Adjuvants 
 
Antigen presenting cells (APCs) such as dendritic cells (DCs) and macrophages 
are the main target immune cell population for most vaccine adjuvants (61). Once 
activated, APCs play a vital role in priming of antigen specific CD4 T-cells, the maestro 
of the adaptive immune response (61). Activation of APCs typically leads to upregulation 
of surface costimulatory molecules such as CD40 and CD80/86 mediate their interaction 
with CD4 T-cells (61). Naïve B-cells have the capacity to present antigens to CD4 T-cells 
as well. There are two broad categories of vaccine adjuvants based on their perceived 
mechanism of action. These two categories are delivery systems and immune potentiators 
(60). In both categories, proper activation of APCs and the subsequent adaptive immune 
response is the target. 
 
Forming a depot of the vaccine antigen at the injection site and delaying antigen 
clearance are the leading hypotheses. In addition, the impartation of a particulate nature 
to vaccine antigens by these adjuvants is believed to increase antigen uptake by APCs. 
Regardless of the precise mechanism, improved antigen presentation by APCs seems to 
be the general outcome of using adjuvants as vaccine vehicles. 
 
Immune potentiators are usually ligands for the pattern recognition receptors 
(PRRs) we previously discussed (see the innate immune section). The most characterized 
as vaccine adjuvants are the ligands for TLRs (60). Upon binding of such adjuvants to 
their specific PRRs, they initiate a signaling cascade that result in secretion of various 
proinflammatory cytokines and chemokines. These proinflammatory “messages” do not 
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only activate APCs but also they dictate the type of the adaptive immune response to be 
activated as well (61). For example signaling through most TLRs leads to secretion of 
IFN-gamma and IL-12 which in turn favors the activation of specific subset of CD4 
T-cells, the Th1 cells (61). The latter cells have been shown to provide the essential 
cytokines needed for proliferation of cytotoxic T-lymphocytes (CTLs) (61). Another 
subset of immune potentiators would be the direct administration of cytokines such as 
IL_2 in combination with the vaccine antigens (60). 
 
 
Mineral Salts 
 
 Mineral salts are the most commonly used vaccine adjuvants in humans (62). 
Insoluble aluminum salts or alum are the only adjuvant that is approved for use in human 
influenza vaccines in the US. Chemically alum composition is variable with aluminum 
oxyhydroxide and aluminum hydroxyphosphate being the most commonly used 
derivatives (63). The use of calcium derivatives has also been reported (63).  
 
There are several mechanisms that have been proposed to explain alum 
adjuvanticity. Firstly, as a classic delivery system, alum is believed to form a depot of the 
vaccine antigen at the site of injection and to improve antigen uptake by APCs (61). 
Recently, several reports have shown that alum is capable of inducing a local 
inflammation at the injection site and this inflammation is correlated with its immune 
enhancing effects (61). These reports have revealed that alum mediates NLRP3 
inflammasome activation and the consequential release of the proinflammatory cytokines 
IL-1 beta and IL-18 (64). Whether the deletion of this pathway significantly impacts the 
adjuvant effects of alum is still controversial (65-67).  
 
Alum has been used with various forms of influenza vaccines for decades (60). 
When used with subunit H5N1 influenza vaccines, the results were inconsistent. While 
Bresson et al. observed a greater response to the adjuvanted vaccine formulation; this was 
only at the highest dose (30 µg) of the vaccine (53). Keitel et al. observed more frequent 
seroconversion responses with the adjuvanted vaccine at the 7.5 µg dose group with no 
significant differences among other groups (68). Additional studies found no evidence for 
a significant adjuvant effect of alum (69). Overall evaluation of alum-adjuvanted subunit 
H5N1 influenza vaccines in humans indicates that alum effect is modest. This is equally 
true for whole virus influenza vaccines as well (70). 
 
 
Emulsions 
 
 Emulsions are the second most commonly used adjuvants in human vaccines. 
Emulsions are prepared by mixing two immiscible liquid phases (aqueous and oily 
phases) in the presence of surfactants. There are two types of emulsions based on the 
nature of the dispersed (or inner) vs. the dispersing (or outer) liquid phase; water-in-oil 
(w/o) and oil-in-water (o/w) emulsions. Despite being efficient adjuvants, w/o emulsion 
adjuvants such as complete Freund’s adjuvant (CFA) are no longer used in human 
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vaccines due to their high reactogenicity (62). On the other hand, oil-in-water emulsions 
such as MF59 and AS03 have been shown to be effective and safer adjuvants (60).  
 
The mechanism of action of emulsion adjuvants is unknown. Initially it was 
thought that similar to other vaccine vehicles, emulsions form a depot of the vaccine 
antigen allowing its slow release from the injection site. However, studies with labeled 
gD2 from type 2 herpes simplex virus (HSV) revealed similar release kinetics between 
the unadjuvanted and the MF59 adjuvanted antigen (71). Similarly to alum, it is proposed 
that MF59 improve antigen uptake by APCs (72). More recently studies with MF59 
adjuvanted vaccines have shown that MF59 stimulates a potent localized inflammatory 
response at the site of injection (73). Unlike alum, the innate immune pathway(s) 
involved in emulsion-based adjuvants induced inflammation is not clear. 
 
 
MF59 
 
 Among the variety of o/w emulsion based adjuvants that have been tested with 
influenza vaccines, MF59 is the most extensively studied (74). The oil phase is 
comprised of 4.3% w/v squalene oil. Two surfactants were used; Tween 80 
(polyoxyethylene sorbitan monooleate) and Span-85 (sorbitan trioleate). Sodium citrate 
buffer (10 nM) is included to improve the emulsion stability (74). In 1997, MF59 has 
been licensed in combination with inactivated influenza vaccine as a seasonal vaccine for 
the elderly in Europe (74).  
 
Initial trials of MF59 with H5 vaccines were performed with the inactivated 
H5N3 whole virus vaccine (75). These studies demonstrated that MF59 had significantly 
boosted the antibody response in comparison to the unadjuvanted vaccine. Similar results 
were reported by Atmar et al. using MF59 in combination with an inactivated influenza 
vaccine derived from H9N2 avian influenza A viruses (76). These initial studies have not 
only demonstrated the ability of MF59 to significantly improve the antibody response to 
influenza vaccines but also its dose sparing capacity. In a comprehensive clinical trial, 
Bernstein et al. showed that MF59 in combination with a subunit H5N1 influenza vaccine 
derived from A/Vietnam/1203/2004 induced more potent anti-H5 antibody responses in 
comparison to the alum adjuvanted or the unadjuvanted formulations (69). These results 
strongly suggest that unless novel production and/or adjuvant systems are developed, 
oil-in-water adjuvants should go hand-in-hand with the development of vaccines for 
potential influenza pandemics.   
 
 
Scope and Objectives of Dissertation 
 
An ideal pre-pandemic H5N1 vaccine formulation should be able to elicit a fast 
and protective antibody response preferably after a single immunization. It also should 
prime a diverse repertoire of H5 specific B cells capable of responding to subsequent 
challenge with as many viral antigenic variants as possible. Preliminary studies have 
shown that the use of the oil-in-water emulsion based adjuvant MF59 in combination 
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with subunit H5N1 influenza vaccines has significantly enhanced the overall immune 
responses not only to the vaccine parent viral strain but also to drifted strains as well. 
However, it remained unclear whether this adjuvant-mediated broadening of the antibody 
responses are resulting from a real expansion of the targeted epitopes within the vaccine 
antigen or due to a general enhancement of the antibody titers, which in turn lead to the 
detection of minor responses that were otherwise undetectable. Considering the 
importance of adjuvants’ impact on the kinetics and the broadness of the protective 
antibody responses, it is surprising that we understand little about the factors involved. 
Finally, determining the underlying mechanisms that mediate adjuvant effects allows for 
the rational design of new adjuvants, which in turn can be utilized to enhance adjuvants’ 
overall efficacy. 
 
 
Specific Aim 1 
 
 To determine, in a ferret model, how soon following a single immunization with 
the prepandemic H5N1 vaccine protection against lethality can be attained and how 
adjuvants would affect the kinetics of such protection. We immunized ferrets with a 
single dose of the H5N1 subunit vaccine either unadjuvanted or adjuvanted with MF59 or 
alum at different time points prior to challenge with a lethal dose of the homologous 
H5N1 virus. 
 
 
Specific Aim 2 
 
To determine whether MF59 afford qualitative or simply quantitative changes in a 
vaccine induced antibody response. Although a number of studies have addressed these 
issues at the level of antibody quantity, little is known about the quality of these 
responses. More specifically, we wanted to determine how the priming environment 
affects the breadth of the antibody responses to HA in the murine model. 
 
 
Specific Aim 3 
 
 To determine the underlying molecular mechanisms that mediate adjuvant effects 
of oil-in-water emulsion adjuvants. We examined the role of the NLRP3 inflammasome 
in the mediating the antibody responses to MF59-adjuvanted H5N1 vaccines. 
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CHAPTER 2.    ADJUVANTS ENHANCE THE KINETICS OF PROTECTIVE 
ANTIBODY RESPONSES TO H5N1 INFLUENZA VACCINES 
 
 
Introduction 
 
 Highly pathogenic avian influenza A (HPAI) viruses are pathogens to which most 
of the human population is immunologically naïve (77). Since 1997, when the first direct 
transmission of the highly pathogenic H5N1 influenza viruses from birds to humans was 
identified in south East Asia, the viruses continued to circulate in birds causing increasing 
number of infections and death (77). From the clinical point of view, the main difference 
between seasonal and HPAI viruses’ infection is the severity of the clinical symptoms 
associated with the latter infection (22). These symptoms typically include pneumonia 
with progressive respiratory failure, gastrointestinal symptoms and liver and renal 
dysfunction (22). Central nervous system involvement has also been reported leading to 
an overall mortality rate of 60% (22). 
 
Vaccination is the most efficient way of controlling influenza and influenza-
related complications. The 1997 and 2003 H5N1 outbreaks have encouraged the World 
Health Organization (WHO) to develop and stockpile prepandemic H5N1 vaccines 
(http://www.who.int/csr/disease/avian_influenza/guidelines/H5VaccineVirusUpdate2008
0214.pdf). These vaccines are to be deployed during the early phases of a pandemic while 
a matching vaccine is developed. A major hurdle in the prepandemic preparedness plan is 
that the vaccine manufacturing capacity does not meet the demand. Moreover and for yet 
unclear reasons, subunit vaccines derived from avian influenza viruses have been shown 
to be poorly immunogenic (8). Clinical trials with subunit H5N1 vaccines have shown 
that two immunizations containing high amounts of antigen (90 µg of hemagglutinin or 
HA) were required to elicit what is considered to be a protective antibody response in 
50% of the study subjects (78). Therefore, the use of adjuvanted influenza vaccines was 
recommended.  
 
 The use of adjuvants to boost influenza vaccines immunogenicity was introduced 
several decades ago (62). A vital advantage of using adjuvants is the ability, using 
smaller quantities of the vaccine antigens, to elicit antibody responses that is equivalent 
those generated using higher quantities of the unadjuvanted vaccine (60). This antigen 
sparing capacity is particularly important in the case of avian influenza vaccines because 
it will allow for broader vaccine coverage. The addition of alum to subunit H5N1 
influenza vaccines has induced only marginal improvements (79). However, the 
oil-in-water emulsion adjuvant MF59 showed more promising results; higher serum 
antibody titers as well as more cross reactive responses when. MF59 is licensed for use in 
seasonal influenza vaccines in Europe (60). MF59 was tested with H5 and H9 vaccines 
and showed promising results in terms of potentiating the immune response with 
evidence of increasing cross reactivity with antigenic variants as well (76). These studies 
strongly suggest that unless novel production and/or adjuvant systems are developed, oil-
in-water adjuvants will become a critical part of pandemic influenza preparedness and 
influenza vaccines in general.  
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Most of the H5N1 vaccine trials, either clinical or preclinical, have tested the 
ability of different vaccine formulations to either induce a serologically protective 
antibody levels or protect vaccinated animals against challenge-mediated mortality three 
to four weeks after the boosting dose. While such information is essential in assessing the 
overall efficacy of the vaccines, in the case of an avian influenza outbreak health care 
workers and individuals involved in outbreak disease control and eradication activities 
will have to engage almost immediately. The Center for Disease Control and Prevention 
(CDC) is recommending that such personnel, in addition to receiving prophylactic 
antiviral drugs, should also be vaccinated with the seasonal influenza vaccines to reduce 
the probability of a co-infection with both human and avian influenza 
(http://www.cdc.gov/flu/avian/professional/infect-control.htm). But seasonal vaccines 
will unlikely provide protection against human infection with the avian viruses. 
Therefore, once an outbreak or a pandemic of H5N1 is declared, vaccinating those 
individuals and other high risk groups with a single dose of the pre-pandemic vaccine 
might be beneficial. Indeed, Middleton et al. found that a single dose of adjuvanted H5N1 
vaccines when administered 4 weeks prior to challenge with H5N1 viruses was able to 
protect ferrets against lethality (80). However, the pre-incubation period between 
administering the vaccine and attaining protection was not determined; yet it is a key 
factor in understanding the full utilization of a prepandemic vaccine (80). 
 
The major aim of the present study was to determine, in a ferret model, how soon 
following a single immunization with the prepandemic H5N1 vaccine protection against 
lethality can be attained and how adjuvants would affect the kinetics of such protection. 
We found that as early as 7 days after immunization with the MF59-adjuvanted vaccine, 
more than 50% of the ferrets survived a highly lethal challenge. We then confirmed our 
results using alum, a different adjuvant system. We believe that these encouraging results 
with the adjuvanted H5N1 vaccines are important in the context of planning various 
strategies to mitigate the early events of a potential H5N1 pandemic. 
 
 
Materials and Methods 
 
 
Viruses 
 
The influenza A/Vietnam/1203/04 (H5N1) virus was obtained from the World 
Health Organization (WHO) collaborating laboratories. Stock virus was grown in the 
allantoic cavities of 9 days old embryonated chicken eggs for 32 h at 36°C, and aliquots 
were stored at −70°C until used. Virus titer was determined by calculating the EID50. 
Experiments with highly pathogenic H5N1 viruses were conducted in a biosafety level 3+ 
containment facility under applicable laws and guidelines. 
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Immunization and Challenge 
 
 Female ferrets 3 months of age and seronegative for currently circulating 
influenza A H1N1, H3N2, and influenza B viruses were obtained from Triple F farms 
(Sayre, PA). Ferrets (3-6 per group) were immunized by intramuscular injection of a 
single 15 µg HA/dose of the pre-pandemic H5N1 vaccine derived from 
A/Vietnam/1203/04 (H5N1) either unadjuvanted or in combination with MF59 or alum. 
At several time points (4, 7, 14 or 21 days) post immunization, ferrets were challenged by 
intranasal inoculation with 106 50% egg infectious doses (EID50) of the highly pathogenic 
A/Vietnam/1203/2004 (H5N1) influenza virus. For the inoculation, ferrets were 
anesthetized with isofluorane and then inoculated intranasally in a total volume of 1 ml. 
All animal experiments were approved by the Animal Care and Use Committee of St. 
Jude and performed in compliance with relevant institutional policies of the National 
Institutes of Health regulation and the Animal Welfare Act. For the next 10 days 
following challenge, animals were closely monitored for clinical signs of infection. 
Animals that developed severe clinical signs in terms of weight loss, lethargy or 
neurological symptoms were euthanized for humane reasons. 
 
 
Virus Titration 
 
 At selected time points after virus inoculation, ferrets were anesthetized with 
ketamine (25 mg/kg), and 0.5 ml of PBS with antibiotics was slowly introduced into each 
nostril, recovered, measured, and brought to a volume of 1.0 ml with sterile PBS 
containing antibiotics. Bovine serum albumin 7.5% was added at a ratio of 1:20 (v/v) as a 
stabilizing agent. Virus was titrated in embryonated chicken eggs and expressed as log10 
EID50 per milliliter. The limit of virus detection was <0.75 log10 TCID50/ml. 
 
 
Serologic Tests 
 
 Ferret sera were obtained prior to challenge and were treated with receptor 
destroying enzyme (Accurate Chemicals and Scientific, New York) overnight at 37ºC, 
heat-inactivated at 56ºC for 30 min, and diluted 1:10 in PBS. Sera were tested by the 
hemagglutination assay (HI) against the homologous A/Vietnam/1203/2004 (H5N1) virus 
using 1.0% horse red blood cells. For antigen-specific ELISA, microtiter plates (Corning, 
Lowell, MA) were coated overnight at 4°C with the recombinant H5 HA protein from 
A/Vietnam/1203/2004 (eEnzyme, Montgomery Village, MD) in PBS. After an overnight 
incubation with serial dilutions of ferrets’ sera, H5-specific IgG antibodies were detected 
with a goat anti-ferret IgG alkaline-phosphatase conjugate (Biotrend, Cologne, Germany) 
diluted 1:1000 in PBS with 1% bovine serum albumin (BSA). The substrate (p-
nitrophenyl phosphate; Sigma-Aldrich, Atlanta, GA) was added, plates were incubated 
for 30 min at room temperature for color development, and OD values were determined 
at 405 nm in an ELISA reader (Biorad, Los Angeles, CA). 
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Results 
 
 
MF59-Adjuvanted H5N1 Vaccine Provides Fast Protection against Challenge-
Associated Mortality and Morbidity 
 
 We examined the protective effect of single dose (15 µg HA/dose) immunization 
with either the unadjuvanted prepandemic H5N1 subunit vaccine derived from 
A/Vietnam/1203/04 (H5N1) or adjuvanted with MF59. Immunizations were given at 3 
different time points (14, 7, or 4 days) prior to challenge with a high dose of the 
homologous virus, A/Vietnam/1203/04 (H5N1) (Table 2-1). For ferrets that received the 
unadjuvanted vaccine 4 days (V4), 7 days (V7) or 14 days (V14) prior to challenge, we 
observed severe clinical symptoms including weight loss, anorexia, neurological signs, 
extreme lethargy, and they all died or had to be euthanized by day 5 post challenge 
(Table 2-1 and Fig. 2-1). Ferrets given the MF59-adjuvanted vaccine 4 days (M4) prior 
to challenge showed similar symptoms to those that received the unadjuvanted vaccine 
and they all died or had to be euthanized by day 5 post challenge for humane reasons 
(Table 2-1). Although four out of the six ferrets that received the MF59-adjuvanted 
immunization 7 days prior to challenge survived, they showed typical symptoms of 
influenza virus infection including weight loss and mild lethargy (Table 2-1 and Fig. 
2-1).  The clinical symptoms were, however, milder than those observed with ferrets that 
received the unadjuvanted vaccine or the M4 group. Two out the six ferrets in the M7 
group developed neurological symptoms and were euthanized 5 and 7 days post 
challenge (Table 2-1). All ferrets given the MF59-adjuvanted vaccine 14 days prior to 
challenge (M14) survived and showed minor clinical signs (Table 2-1 and Fig. 2-1). 
These data show that a protective response can be generated in as little as 7 days 
following immunization with a single dose of the adjuvanted subvirion H5N1 influenza 
vaccine. 
 
 
Kinetics of the Antibody Response to the MF59-Adjuvanted H5N1 Vaccines 
 
 We tested the induction of H5 specific antibodies in the ferrets’ sera prior to 
challenge. Not surprisingly, ferrets that received the unadjuvanted vaccine (V4, V7 and 
V14 groups) failed to develop a detectable H5 specific antibody titer measured either by 
hemagglutination inhibition (HI) or ELISA (Table 2-2). Similarly, we failed to detect H5 
specific antibodies in sera collected from M4 group (Table 2-2). Although four out of the 
six ferrets that were immunized with the MF59-adjuvanted vaccine 7 days prior to 
challenge survived, we also failed to detect H5 specific titers these animals’ sera (Table 
2-2). Expectedly, H5 specific titers were detectable in sera of the ferrets that belonged to 
M14 group by HI and ELISA titers of 16.6 and 300, respectively (Table 2-2). These data 
show that the presence of detectable antibody titers is predictive of protection but also 
that a lack of detectable titers as measured by HI or ELISA is not necessarily predictive 
of death. To assess the ability of the different immunization regimens to prevent virus 
replication in the upper respiratory tract of ferrets, we determined viral titers in nasal 
wash samples on day 5 post inoculation (Table 2-2). 
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Table 2-1. Effect of the different vaccination regimen on survival and clinical signs of infection in ferrets challenged with 
A/Vietnam/1203/04 (H5N1) influenza virus. 
 
Group 
name 
Vaccination regimen (days 
prior to challenge)a 
No. 
dead/ 
total no. 
Time of death, 
days after 
infection 
Clinical signsb 
Respiratory 
symptoms 
Neurological 
symptoms 
Lethargy 
(RII)c 
V4 15 µg H5N1 Vaccine (4) 3/3 4, 4, 5 3/3 2/3 3.0 
V7 15 µg H5N1 Vaccine (7) 3/3 4, 5, 5 2/3 2/3 2.5 
V14 15 µg H5N1 Vaccine (14) 3/3 5, 5, 5 2/3 2/3 3.0 
M4 15 µg H5N1 Vaccine + MF59 (4) 3/3 3, 4, 5 3/3 3/3 3.0 
M7 15 µg H5N1 Vaccine + MF59 (7) 2/6 5, 7 3/6 2/6 1.5 
M14 15 µg H5N1 Vaccine + MF59 (14) 0/5 - 0/5 0/5 0.0 
 
a Ferrets were immunized with a single 15 µg dose of the H5N1 SU vaccine derived from A/Vietnam/1203/04 (H5N1) with or  
without MF59. After the indicated number of days after immunization, ferrets were challenged by inoculation with 106 EID50 
of A/Vietnam/1203/04 virus. 
b Clinical signs were observed for 10 days after virus inoculation. Except for lethargy and weight loss, findings for clinical 
signs are given as no. of ferrets with sign/total no. Respiratory signs included sneezing, wheezing, and nasal discharge; 
neurological signs included hind limb paresis, ataxia, torticollis, and tremors. 
c The relative inactivity index (RII) is scored as follows: 0, alert and playful; 1, alert, playful when stimulated; 2, alert but not 
playful when stimulated; 3, neither alert nor playful when stimulated (81).
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Table 2-2. Effect of different vaccination regimen on A/Vietnam/1203/04 (H5N1) 
influenza virus replication in the upper respiratory tract of ferrets. 
 
Groupa HI titer ELISA titer(IgG) 
No. shedding/ total no. of 
ferrets testedb Virus titer
c 
V4 < < NAd NA 
V7 < < 2/3 4.3 (±0.35) 
V14 < < 3/3 4.5 (±0.25) 
M4 < < NA NA 
M7 < < 3/3 4.0 (±0.38) 
M14 16.6 300 1/3 2.5 
 
a Vaccination regimen for these groups is shown in Table 2-1. 
b Based on the viral titers measured in the nasal washes collected 5 days post challenge 
with 106 EID50 of A/Vietnam/1203/04 virus. The assay detection limit was 0.75 log10 
EID50/mL. 
c Titers (from day 5 nasal washes and expressed as log10 EID50/mL) are given as means ± 
SD, unless only 1 animal was shedding virus. 
d NA, not applicable, only one animal from these groups survived to day 5. 
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All ferrets that were immunized with the unadjuvanted vaccine and survived to 
day 5 shed virus at high titers (4.3 and 4.5 log10 EID50/mL for V7 and V14 groups 
respectively). M7 ferrets shed virus to similar extent (4.0 log10 EID50/mL). Only one 
ferret from the M14 group was shedding detectable viral titer at day 5 post challenge 
(Table 2-2). The virus titer shed by this animal was 1.5 logs less than virus titers shed by 
ferrets that belonged to the unadjuvanted vaccine (V7 and V14) or M7 groups (2.5 log10 
EID50/mL, Table 2-2).  
 
 
Impact of Alum on H5N1 Vaccine-Mediated Protection Kinetics 
 
 We next assessed whether a similarly early protective response could be 
generated after a single immunization with the prepandemic H5N1 vaccine combined 
with a different adjuvant. Similar to MF59, alum has been licensed to be used in 
combination with human influenza vaccines. To this end, we used the same single 
immunization followed by challenge approach to test whether alum-adjuvanted H5N1 
vaccine can provide the early protection that we observed with the MF59-adjuvnated 
vaccine. Based on the assumption made from clinical trials that alum would be inferior to 
MF59 in adjuvant activity, immunizations were given at three different time points (21, 
14 and 7 days) prior to challenge. We used an immunization dose of 15 µg HA/dose. As 
shown in Table 2-3, ferrets belonging to the three groups (A7, A14 and A21) survived 
the lethal challenge. However, ferrets that received the immunization seven days prior to 
challenge or A7 group suffered a modest weight loss (11.1%) and 2 out of 3 ferrets 
showed respiratory signs of infection in addition to be mildly lethargic (Table 2-3).  
 
Similarly to what was observed with MF59-adjuvanted vaccine, A14 and A21 
groups showed minimal clinical symptoms after challenge with no weight loss by day 5 
post challenge (Table 2-3). This lack of challenge associated morbidity in the A14 and 
A21 groups correlated well with the development of detectable H5 specific HI (23.3 and 
46.6, respectively) and IgG (900 and 1140, respectively) titers prior to challenge (Table 
2-4). It also correlated with the lack of detectable viral titers in the nasal washes collected 
from these ferrets 5 days post challenge (Table 2-4). For A7 ferrets, similar to surviving 
ferrets in the M7 group, there were no detectable anti-H5 antibody titers prior to 
challenge (Table 2-4). However and consistent with the milder clinical symptoms 
observed in A7 compared to M7 ferrets, 2 out of the 3 ferrets in A7 group cleared the 
virus by day 5 post challenge (Table 2-4). From these results it is possible to conclude 
that in the H5N1 ferret model, alum is as effective, if not more so, as MF59 in inducing a 
rapid protective immune response when combined with H5N1 prepandemic vaccines. 
 
 
Discussion 
 
 Preventive vaccination, antiviral drugs and non-pharmaceutical interventions 
(such as school closure) are the main public health measures needed to contain an 
influenza pandemic. The major drawback of anti-influenza antiviral drugs (M2 ion 
channel blockers and NA inhibitors) is the development of drug resistance mutants and 
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Table 2-3. Impact of Alum-adjuvanted H5N1 SU vaccine on survival and clinical signs of infection in ferrets challenged 
with A/Vietnam/1203/04 (H5N1) influenza virus. 
 
Group 
name 
Vaccination regimen (days 
prior to challenge)a 
No. 
dead/ 
total no. 
Clinical signsb 
Respiratory 
symptoms 
Neurological 
symptoms 
Lethargy 
(RII)c 
Weight 
lossd 
A7 15 µg H5N1 Vaccine + Alum 
(7) 
0/3 2/3 0/3 1.0 11.1 
A14 15 µg H5N1 Vaccine + Alum 
(14) 
0/3 1/3 0/3 0.0 -0.4 
A21 15 µg H5N1 Vaccine + Alum 
(21) 
0/3 0/3 0/3 0.0 -1.6 
V21 15 µg H5N1 Vaccine (21) 3/3 3/3 3/3 3/3 20.0 
 
a Ferrets were immunized with a single 15 µg dose of the H5N1 SU vaccine derived from A/Vietnam/1203/04 (H5N1) 
adjuvanted with Alum. After the indicated number of days after immunization, ferrets were challenged by inoculation with 
106 EID50 of A/Vietnam/1203/04 (H5N1) virus. 
b Clinical signs were observed for 10 days after virus inoculation. Except for lethargy and weight loss, findings for clinical 
signs are given as no. of ferrets with sign/total no. Respiratory signs included sneezing, wheezing, and nasal discharge; 
neurological signs included hind limb paresis, ataxia, torticollis, and tremors. 
c The relative inactivity index (RII) is scored as follows: 0, alert and playful; 1, alert, playful when stimulated; 2, alert but not 
playful when stimulated; 3, neither alert nor playful when stimulated (81). 
d Calculated as the mean percentage of weight loss 5 days post challenge (as compared to weight at challenge day).
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Table 2-4. Serological titers and viral load in ferrets immunized with Alum-
adjuvanted H5N1 SU vaccine and challenged with A/Vietnam/1203/04 (H5N1) influenza 
virus. 
 
Groupa HI titer 
ELISA titer
(IgG) 
No. shedding/ total no. of 
ferrets testedb Virus titer
c 
A7 < < 1/3 3.5 
A14 23.3 900 0/3 NA 
A21 46.6 1140 0/3 NA 
 
a Vaccination regimen for these groups is shown in Table 2-3. 
b Based on the viral titers measured in the nasal washes collected 5 days post challenge 
with 106 EID50 of A/Vietnam/1203/04 virus. The assay detection limit was 0.75 log10 
EID50/mL. 
c Titers (from day 5 nasal washes and expressed as log10 EID50/mL) are given as means ± 
SD, unless only 1 animal was shedding virus. 
NA, not applicable. 
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the scarcity of novel drugs. Several studies (based on mathematical modeling) have 
suggested that early non-pharmaceutical intervention that would increase social 
distancing may limit the total number of cases and deaths caused by an emerging 
pandemic influenza (82-84). However, the efficiency of applying these measures in 
different communities will be variable. Therefore, prepandemic vaccines remain the 
cornerstone of pandemic preparedness efforts (77). For more than a decade, avian H5N1 
influenza viruses have been a major source of public health concern and continue to pose 
a pandemic threat (77).Given the high mortality rate associated with human infection 
with avian H5N1 viruses, protection from lethality rather than infection is the paramount 
goal of various interventions. The preliminary results of this study show, for the first 
time, that a single adjuvanted 15 µg dose of the prepandemic H5N1 subunit vaccine can 
be protective when administered 7 days prior to lethal H5N1 challenge. Single 
immunization with the MF59-adjuvanted prepandemic vaccine 14 days prior to challenge 
resulted in 100% survival and prevented the development of clinical signs. Shortening the 
pre-challenge incubation period to 7 days resulted in partial protection (66-100% survival 
mild clinical symptoms). Further shortening of the pre-challenge incubation period to 4 
days resulted in loss of protection (no survival and severe clinical symptoms). The 
unadjuvanted prepandemic vaccine failed to provide any protection regardless of the 
length of the pre-challenge incubation. However, it is important to note that the challenge 
dose (106 EID50/ml) was highly lethal (around 104 LD50). It is reasonable to assume that 
with a lower dose, we could have started to see protection in ferrets immunized with the 
unadjuvanted vaccine.  
 
Our preliminary data support what was previously shown by Middleton et al. that 
a single immunization of adjuvanted prepandemic H5N1 vaccine can protect ferrets from 
challenge-associated mortality in a ferret model (80). In the latter study, however, ferrets 
were challenged four weeks after immunization; with most of the ferrets had 
seroconveretd. Our results indicate that the protection from challenge associated death 
and morbidity observed for M14 ferrets can be correlated with the development of 
detectable H5 specific antibody titers in the sera prior to challenge. The anti-H5 titers can 
be also correlated with decreased load and faster clearance of virus from the upper 
respiratory tract of M14 ferrets. For H5N1 subunit vaccines, either adjuvanted or 
unadjuvanted, a pre-challenge incubation period of 4 days was not sufficient to develop 
an adaptive immune response that can protect against challenge-associated morbidity or 
mortality. 
 
In our study, it was surprising to see that within the M7 and A7 groups, surviving 
ferrets did not have any detectable anti-H5 antibody titers either by HI or ELISA. It is 
important to note that the M7 and A7 ferrets were not completely protected from 
challenge-associated morbidity. Whereas M14, A14 and A21 ferrets showed minimal 
clinical symptoms indicating that after a single immunization with an adjuvanted H5N1 
vaccine a prechallenge incubation period of 14 days or longer is sufficient for developing 
protective immune antibody titers. One possible explanation for the early protection 
against lethality observed in M7 and A7 groups is the development of low affinity 
H5-specific IgM antibodies.  
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 Ferrets are the ideal model for influenza vaccination studies due to the 
similarities in susceptibility and disease progression between ferrets and humans in the 
context of influenza infection (26). However, it is important to note that most of the 
human population, unlike naïve ferrets, is not naïve to influenza virus infection. We were 
not able to detect any H5 specific antibodies in the sera of ferrets that received the 
unadjuvanted H5N1 vaccine. However, it is important to note that in the case of human 
immunizations it is possible that cross reactive CD4+ T-cells generated via previous 
exposure to seasonal influenza viruses in the form of vaccination or infection would play 
a role in generating anti-H5 immune response to individuals even if they were not 
previously primed with H5 vaccines (85). Moreover, cross reacting CD8+ T-cells 
generated upon infection with seasonal influenza viruses can also play a role in the 
protection against infection with H5N1 viruses (85). We have recently shown that 
exposure to seasonal influenza viruses immunologically primed for a more robust 
antibody response to the 2009 H1N1 monovalent inactivated vaccine (86). The protection 
was partially mediated by cross reacting CD8+ T-cells (86). This was despite the lack of 
detectable cross neutralizing antibody responses between the seasonal and the 2009 
pandemic H1N1 influenza viruses (39, 86). 
 
Since their emergence, H5N1 viruses have evolved into at least 10 
phylogenetically and antigenically different clades and multiple subclades (87). While 
only four of these clades have been associated with human infections, we are unable to 
predict which clade will acquire the ability to transmit efficiently among humans and thus 
cause a pandemic (87). In our study, we used a homologous challenge approach; the 
vaccine antigen and the challenge virus belonged to the same clade. The kinetics of 
developing protective antibody responses will vary depending on how closely or distantly 
related the vaccine antigen and the challenge virus in terms of antigenicity. However, in 
addition to its ability to significantly enhance the immunogenicity of subunit influenza 
vaccines, MF59 was shown to broaden the antibody responses to seasonal and avian 
influenza vaccines (88, 89). Moreover, MF59 was shown to expand the repertoire of the 
responding antibodies compared to the unadjuvanted subunit H5N1 vaccines (59).  
 
Another important aspect of controlling an emerging influenza pandemic is the 
ability to limit virus transmission from infected individuals to healthy ones (77). While 
we have shown enhanced viral clearance in ferrets immunized with the adjuvanted 
vaccines 14 or 21 days prior to challenge, our results do not exclude the possibility that 
those ferrets were still able to transmit the virus early after infection. Also it will be 
important to determine the duration of this protective response and whether a booster 
immunization will be needed to keep the protective antibody levels. 
 
Milne et al. investigated (using simulation math models) the optimum strategies 
for utilizing the stockpiled pre-pandemic human H5N1 vaccines (90). However, in this 
study (and other similar studies) it is assumed that two doses of the vaccine will be 
required for full protection (90). This assumption was based the observations that 
individuals do not seroconvert prior to receipt of a second dose (91) and the lack of 
experimental data regarding the time needed to develop protective immune response 
following immunization. Based on our results, we think such assumptions will need to be 
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reevaluated. From the public health perspective, eliciting an early, within 7 days, 
protective antibody response with a single immunization has two important implications; 
it would significantly decrease the amount of antigen required per individual to achieve 
protection and consequentially expand the vaccine coverage. Secondly, as several reports 
have indicated, the sole dependence on serological titers as an indicator for protection 
needs to be reassessed.  
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CHAPTER 3.    ADJUVANTS’ IMPACT ON THE BREADTH OF THE 
ANTIBODY RESPONSES TO SUBUNIT H5N1 INFLUENZA VACCINES 
 
 
Introduction 
 
Since their emergence in 1996, the goose Guangdong lineage of H5N1 viruses 
have evolved into at least 10 phylogenetically and antigenically distinct clades (92). Our 
scientific knowledge falls short of being able to predict which of these clades could adapt 
to humans and potentially cause a pandemic. Ideally, H5N1 vaccines should stimulate 
antibody responses that target as many of the shared epitopes present within the 10 clades 
as possible. Considering the importance of a diversified antibody response to HA within 
influenza vaccines, it is surprising that we understand little about the factors involved in 
driving such a response.  
 
Due to their poor immunogenicity, the use of adjuvants with pre-pandemic H5N1 
influenza vaccines is strongly recommended 
(http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf). 
Bernstein and colleagues have reported that the antibody titers elicited by unadjuvanted 
or alum-adjuvanted H5N1 vaccines are significantly lower than those observed with 
vaccines that included the oil-in-water adjuvant, MF59 (69). MF59 has been shown, in 
multiple clinical trials with both seasonal and pandemic vaccines, to enhance antibody 
titers to homologous influenza strains and to also provide immunity to antigenically 
distinct virus strains (93-95). In the context of pre-pandemic vaccines, where the potential 
target virus is unknown, such a broad response is very desirable. Despite these claims, 
however, it is a little unclear if the cross reactivity noted is due to a qualitative difference 
in the specificity of the antibody response or if it is simply a reflection of the higher 
overall titers, i.e., the specificity of an adjuvanted vaccine induced antibody is the same 
but that minor populations have been elevated to above detectable levels. Malherbe and 
colleagues have shown that different adjuvants can promote the accumulation of distinct 
dominant clonotypes of CD4+ T-cells in the context of protein vaccination (96). These 
authors concluded that, perhaps due to differential activation of dendritic cell 
populations, different adjuvants can modify the TCR-based selection threshold. As such 
the pressure for selection of dominant T cell clones is altered resulting in functionally 
different response (96). These data suggest that including adjuvants induce qualitative 
differences in the humoral response to vaccination, either through direct adjuvant action 
on antigen presentation to B cells or, indirectly, through differential T helper function. 
 
The aim of this chapter was to investigate the diversity of an antibody response to 
H5N1 vaccines generated under different priming environments. Although a number of 
studies have addressed these issues at the level of antibody quantity, little is known about 
the quality of these responses. To address this issue, we evaluated the B-cell responses in 
mice primed with unadjuvanted, alum-adjuvanted, or MF59-adjuvanted 
H5N1-inactivated vaccine. 
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Materials and Methods 
 
 
Viruses 
 
 The influenza A/Vietnam/1203/04 (H5N1) virus was obtained from the World 
Health Organization (WHO) collaborating laboratories. Stock virus was grown in the 
allantoic cavities of 9‐day‐old embryonated chicken eggs for 32 h at 36°C, and aliquots 
were stored at −70°C until used. Virus titer was determined by calculating the egg 
infectious dose 50 (EID50). 
 
 
Mice and Immunization 
 
 C57BL/6 mice were housed in a pathogen-free facility, and the animal studies 
were conducted under protocols approved by the St. Jude Children’s Research Hospital 
Committee on Use and Care of Animals. Animals were immunized intramuscularly with 
the monovalent H5N1 influenza (rgA/Vietnam/1203/2004) subvirion vaccine (Aventis 
Pasteur Inc., Swiftwater, PA) either unadjuvanted (in PBS), mixed with MF59 (1:1) or 
adsorbed to aluminium hydroxide at 14.1 mg/ml Alum, 3 μg/ml antigen and 5 mM 
Histidine buffer pH 6.5 at 4°C overnight. Each mouse dose contained 500 μg alum. For 
all immunizations, the period between the priming and boosting dose was three weeks. 
The intranasal infections were performed with 100 egg infectious dose 50 of the rg 
A/Vietnam/1203/2004 diluted in PBS to a final volume of 30 µl.  
 
 
Hemagglutination Inhibition Assay 
 
PBS containing four agglutinating units of A/Vietnam/1203/2004 (H5N1) virus 
was incubated with serial 2-fold dilutions of RDE-treated serum samples (starting at a 
1:10 dilution) at room temperature for 30 minutes. The HI titers of the samples were 
determined by testing agglutination of 0.5% of chicken red blood cells. 
 
 
Elispot Assay 
 
Ninety-six-well nitrocellulose-bottomed multiscreen HA filtration plates 
(Millipore, Billerica, MA) were coated (0.1 μg/well) with H5 protein of the 
A/Vietnam/1203/2004 (H5N1) virus (e.Enzyme, Montgomery Village, MD). After 
overnight incubation at 4°C, the plates were washed with PBS and subsequently blocked. 
Next, different dilutions of bone marrow cell suspensions were added in volumes of 100 
μl/well. After 4 hours of incubation at 37°C in a humidified atmosphere containing 5% 
CO2, the plates were washed with PBS, and alkaline phosphatase-conjugated goat anti-
mouse IgG (SouthernBiotech, Birmingham, AL) diluted in PBS containing 5% bovine 
serum albumin was added (100 μl/well) and incubated overnight at 4°C. Spots were 
developed by adding 100 μl/well of BCIP/NBT phosphatase substrate (Kirkegaard & 
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Perry Laboratories, Gaithersburg, MD), then counted with an Olympus SZX9 stereozoom 
microscope for analysis using KS Elispot software (Zeiss, Thornwood, NY).  
 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 
In brief, microtiter plates (Corning Inc., Corning, NY) were coated overnight at 
4°C (0.1 μg/well) with H5 protein of the A/Vietnam/1203/2004 (H5N1) virus (e.Enzyme, 
Montgomery Village, MD). Plates were then washed with PBS containing 0.05% Tween 
20 and subsequently blocked. Influenza-specific antibody responses were detected with 
goat anti-mouse IgM, IgG, IgG1, IgG2b, IgG2c, IgG3, or IgE conjugated to alkaline 
phosphatase (SouthernBiotech, Birmingham, AL). A substrate (p-nitrophenyl phosphate; 
Sigma-Aldrich, St. Louis, MO) was added, plates were incubated for 30 minutes at room 
temperature for color development, and optical density values were determined at 405 nm 
in an ELISA reader (Molecular Devices, Sunnyvale, CA). Titers were presented as the 
highest dilution that yielded an optical density three times greater than that of a 1/100 
dilution of pre-immune serum. Serum IgG levels were determined using a mouse IgG 
ELISA kit (Life Diagnostics, West Chester, PA). 
 
 
Competitive ELISA 
 
The H5 specific human mAbs were purified on protein A or G columns (GE 
Healthcare, Smyrna, GA). The competition between murine polyclonal serum antibodies 
and human mAbs for binding to immobilized antigens was measured by ELISA. Briefly, 
the mAbs were added to HA-coated plates at a high concentration (10 mg/ml). After 1 
hour, plasma samples were added at a concentration corresponding to 70%–80% of the 
maximal OD level, and the mixture was incubated at room temperature for 1 hour. Plates 
were then washed and bound sera were detected using AP-labeled anti-mouse IgG 
antibodies (Southern biotech, Birmingham, AL). The percentage of inhibition was tested 
in duplicates and calculated as follows: [(ODno-competition – ODcompetition)/   (ODno-competition)] 
× 100.  
 
 
Flow Cytometry  
 
Mice were euthanized via CO2  inhalation and inguinal lymph nodes were 
harvested after immunization. Lymph nodes were manually disrupted by grinding organ 
tissue between the frosted ends of two sterile glass microscope slides in sterile PBS 
containing 2% fetal bovine serum. Cells were then labeled with anti-CD16/CD32 (clone 
2.4G2, BD PharMingen, San Diego, CA) to block nonspecific Fc receptor-mediated 
binding. After washing, cells were stained with different combinations of fluorescently 
labelled antibodies against CD8α (clone 53-6.7, BD PharMingen), CD4 (clone RM4-5, 
BD PharMingen), CD11b (M1/70, Biolegend, San Diego, CA), IgD (11-26c.2a, BD 
PharMingen), CD138 (281-2, BD PharMingen), B220 (RA3-6B2, BD PharMingen), FAS 
(Jo2, BD PharMingen), and GL7 (BD PharMingen). Labeled cells were assayed with a 
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FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ) and data were 
analyzed using FlowJo (Tree Star, Ashland, OR) software. 
 
 
PCR Amplifications and High-Throughput Pyrosequencing and Analysis of the 
Immunoglobulin Heavy Chain Variable Genes 
 
PCR amplifications were performed using total RNA as template for each 
reaction. Following PCR, amplicons were then purified by 1.5% agarose gel 
electrophoresis and gel extraction as described previously. PCR was performed using 
primers that were previously described (97) but were modified to fit the 454 technology. 
High-throughput amplicon pyrosequencing data obtained with a 454 instrument 
performed using the Titanium chemistry, with amplicons sequencing reads beginning 
from the “A” primer in the manufacturer’s protocol in both cases (Roche, Branford, CT). 
Additional 12-nt sample bar codes were incorporated into the multiplexed IGHV gene 
segment primers. Sequence bar codes allowed for the pooling and bulk sequencing of 
many libraries and the subsequent retrieval of sequences that were derived from each 
sample. The sequences were analyzed using the data base ImMunoGeneTics 
(http://imgt.cines.fr/) and the number of non-silent mutations within the variable genes 
was compared. Clonal analysis was performed on these sequences based on the 
assumption that if two or more sequences shared the same variable heavy chain, diversity 
and junction genes usage and the same junction sequence, these sequences are considered 
a clonal pool. The number of non-silent mutations was determined for each clonal pool.  
 
 
H5 Antigen Microarray 
 
Antigen arrays are a high-throughput assay that builds upon the technology of 
DNA microarrays. Slides coated with an epoxy surface were spotted using a robotic 
microarray printer. The slides were printed with 54 of overlapping 18mers spanning the 
full length of H5 HA from A/Vietnam/1203/2004 (H5N1) (Table 3-1). Slides were then 
blocked in BSA 1% and then incubated with purified IgG (Protein G, GE Healthcare, 
Smyrna, GA) from the sera derived from naïve and immunized C57bl/6 mice. After 
washing, the slides were incubated with a 2nd anti-IgG that are fluorescent tagged. Slides 
are washed, dried and then scanned in a laser scanner. 
 
 
Statistical Analysis 
 
Statistical analyses were performed using InStat (GraphPad, La Jolla, CA) 
software. In most cases, the Mann-Whitney (non-parametric) test was used to compare 
results. 
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Table 3-1. List of peptide sequences that are used to coat H5 microarray chips. 
 
No. Sequence No. Sequence 
1 K-I-V-L-L-F-A-I-V-S-L-V-K-S-D-Q-I-C 28 V-K-K-G-D-S-T-I-M-K-S-E-L-E-Y-G-N-C 
2 L-V-K-S-D-Q-I-C-I-G-Y-H-A-N-N-S-T-E 29 S-E-L-E-Y-G-N-C-N-T-K-C-Q-T-P-M-G-A 
3 Y-H-A-N-N-S-T-E-Q-V-D-T-I-M-E-K-N-V 30 K-C-Q-T-P-M-G-A-I-N-S-S-M-P-F-H-N-I 
4 D-T-I-M-E-K-N-V-T-V-T-H-A-Q-D-I-L-E 31 S-S-M-P-F-H-N-I-H-P-L-T-I-G-E-C-P-K 
5 T-H-A-Q-D-I-L-E-K-K-H-N-G-K-L-C-D-L 32 L-T-I-G-E-C-P-K-Y-V-K-S-N-R-L-V-L-A 
6 H-N-G-K-L-C-D-L-D-G-V-K-P-L-I-L-R-D 33 K-S-N-R-L-V-L-A-T-G-L-R-N-S-P-Q-R-E 
7 V-K-P-L-I-L-R-D-C-S-V-A-G-W-L-L-G-N 34 L-R-N-S-P-Q-R-E-R-R-R-K-K-R-G-L-F-G 
8 V-A-G-W-L-L-G-N-P-M-C-D-E-F-I-N-V-P 35 R-K-K-R-G-L-F-G-A-I-A-G-F-I-E-G-G-W 
9 C-D-E-F-I-N-V-P-E-W-S-Y-I-V-E-K-A-N 36 A-G-F-I-E-G-G-W-Q-G-M-V-D-G-W-Y-G-Y 
10 S-Y-I-V-E-K-A-N-P-V-N-D-L-C-Y-P-G-D 37 M-V-D-G-W-Y-G-Y-H-H-S-N-E-Q-G-S-G-Y 
11 N-D-L-C-Y-P-G-D-F-N-D-Y-E-E-L-K-H-L 38 S-N-E-Q-G-S-G-Y-A-A-D-K-E-S-T-Q-K-A 
12 D-Y-E-E-L-K-H-L-L-S-R-I-N-H-F-E-K-I 39 D-K-E-S-T-Q-K-A-I-D-G-V-T-N-K-V-N-S 
13 R-I-N-H-F-E-K-I-Q-I-I-P-K-S-S-W-S-S 40 G-V-T-N-K-V-N-S-I-I-D-K-M-N-T-Q-F-E 
14 I-P-K-S-S-W-S-S-H-E-A-S-L-G-V-S-S-A 41 D-K-M-N-T-Q-F-E-A-V-G-R-E-F-N-N-L-E 
15 A-S-L-G-V-S-S-A-C-P-Y-Q-G-K-S-S-F-F 42 G-R-E-F-N-N-L-E-R-R-I-E-N-L-N-K-K-M 
16 Y-Q-G-K-S-S-F-F-R-N-V-V-W-L-I-K-K-N 43 I-E-N-L-N-K-K-M-E-D-G-F-L-D-V-W-T-Y 
17 V-V-W-L-I-K-K-N-S-T-Y-P-T-I-K-R-S-Y 44 G-F-L-D-V-W-T-Y-N-A-E-L-L-V-L-M-E-N 
18 Y-P-T-I-K-R-S-Y-N-N-T-N-Q-E-D-L-L-V 45 E-L-L-V-L-M-E-N-E-R-T-L-D-F-H-D-S-N 
19 T-N-Q-E-D-L-L-V-L-W-G-I-H-H-P-N-D-A 46 T-L-D-F-H-D-S-N-V-K-N-L-Y-D-K-V-R-L 
20 G-I-H-H-P-N-D-A-A-E-Q-T-K-L-Y-Q-N-P 47 N-L-Y-D-K-V-R-L-Q-L-R-D-N-A-K-E-L-G 
21 Q-T-K-L-Y-Q-N-P-T-T-Y-I-S-V-G-T-S-T 48 R-D-N-A-K-E-L-G-N-G-C-F-E-F-Y-H-K-C 
22 Y-I-S-V-G-T-S-T-L-N-Q-R-L-V-P-R-I-A 49 C-F-E-F-Y-H-K-C-D-N-E-C-M-E-S-V-R-N 
23 Q-R-L-V-P-R-I-A-T-R-S-K-V-N-G-Q-S-G 50 E-C-M-E-S-V-R-N-G-T-Y-D-Y-P-Q-Y-S-E 
24 S-K-V-N-G-Q-S-G-R-M-E-F-F-W-T-I-L-K 51 Y-D-Y-P-Q-Y-S-E-E-A-R-L-K-R-E-E-I-S 
25 E-F-F-W-T-I-L-K-P-N-D-A-I-N-F-E-S-N 52 R-L-K-R-E-E-I-S-G-V-K-L-E-S-I-G-I-Y 
26 D-A-I-N-F-E-S-N-G-N-F-I-A-P-E-Y-A-Y 53 K-L-E-S-I-G-I-Y-Q-I-L-S-I-Y-S-T-V-A 
27 F-I-A-P-E-Y-A-Y-K-I-V-K-K-G-D-S-T-I 54 L-S-I-Y-S-T-V-A-S-S-L-A-L-A-I-M-V-A 
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Results 
 
 
MF59 is Superior to Alum in Priming for Robust H5-Specific Antibody Responses 
 
HA-specific antibodies are considered the most important correlate of protection 
elicited by inactivated influenza vaccines. It was previously shown that in mice MF59 is 
superior to alum and several other adjuvants in priming for a robust antigen-specific 
humoral immune response when combined with seasonal influenza vaccines (98). To test 
this observation in the context of pre-pandemic H5N1 vaccines, we primed four groups of 
WT C57BL/6 mice with H5N1 subvirion vaccines (MF59-, alum-adjuvanted or 
unadjuvanted) or with sub lethal H5N1 influenza virus (homologous to the vaccine strain) 
infection. After boosting all groups with the unadjuvanted H5N1 subvirion vaccine in 
phosphate buffered saline (PBS), we first determine the serum levels of H5-specific IgG 
antibodies induced. We found that mice primed with the MF59 adjuvanted vaccine 
elicited significantly higher antibody titers than the alum-adjuvanted and unadjuvanted 
vaccine-primed mice, though they were comparable to those elicited in the 
infection-primed mice (Fig. 3-1A). Mean pre-boost titers for the MF59, alum and 
unadjuvanted vaccine groups were 3400, 362.5 and 25 respectively. We next determined 
the frequency of H5-specific antibody forming cells (AFCs) in the bone marrow and 
spleen after the boosting immunization. For the unadjuvanted vaccine-primed mice, the 
number of AFCs was below the assay detection limit (Fig. 3-1B-C). However, and 
consistent with the serum IgG results, the number of H5-specific IgG forming cells was 
comparably elevated in the MF59- and infection-primed mice and was significantly 
higher than that observed in alum-primed mice (Fig. 3-1B-C). 
 
 
MF59 and Alum Enhance the Affinity Maturation of the B-Cell Response to H5N1 
Vaccine   
 
 One of the important aspects of adjuvants’ impact on the antibody responses to 
immunization is their ability to enhance the affinity of vaccine specific antibodies (99). 
Affinity maturation is believed to occur in the B-cell follicles during the germinal center 
reaction where B-cell receptors are subjected to multiple rounds of mutations known as 
somatic hypermutation (100). Emerging B-cell clones with the highest affinity gain a 
survival advantage and they form a pool of memory B-cells and long lived plasma cells 
(100). This process requires CD4+ T-cell help. These mutations are largely clustered in 
the complementarity determining regions of the antibody variable genes (101). We 
investigated the impact of MF59 and alum on the maturity of B-cell responses to H5N1 
vaccines. Spleenocytes from mice immunized as described in Fig. 3-1 were harvested 5 
days following the final boost and the total number of B-cells differentiated into germinal 
center B-cells (GCs) in the different groups was determined. Consistent with the antibody 
titers, priming with the MF59-adjuvanted H5N1 vaccine led to a greater accumulation of 
B-cells within GCs compared to the unadjuvanted or the alum-adjuvanted vaccine (Fig. 
3-2A). The MF59 induced GC accumulation was equivalent to that observed in mice 
primed with sublethal H5N1 infection (Fig. 3-2A).  
  
F
f
 
F
a
w
l
r
i
igure 3-1. S
ormulations. 
our groups of C
lum-adjuvanted
ith 3 µg of H5
evels of H5-spe
esults are repre
ndicated with a
uperior priming
57BL/6 wild-t
 or unadjuvant
N1 subvirion va
cific IgG antibo
sentative of at l
sterisks; *, p<0
 with MF59-ad
ype mice (n=5)
ed) or with sub 
ccine in PBS a
dies. (B) Mean
east 2 separate e
.05. ns, not sign
juvanted H5N1
 were intramusc
lethal A/vietnam
nd five days aft
 number of H5-
xperiments. St
ificant. nd, not 
40 
 vaccines in com
ularly primed e
/1203/2004 (H
er the boost ser
specific IgG for
atistically signif
detectable. Erro
parison to the 
ither with 1 µg 
5N1) influenza
a and other orga
ming cells in th
icant difference
r bars show sta
alum-adjuvant 
of H5N1 subvi
 virus infection
ns were harves
e bone marrow
s between WT 
ndard error.
 
or the unadjuva
rion vaccine (M
. All groups we
ted. (A) Mean c
 and (C) spleen
and mutant gro
nted 
F59-, 
re boosted 
irculating 
. The 
ups are as 
  
Figur
and M
 
Four 
µg of
lethal
with 
germ
numb
show
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e 3-2. In
F59-adjuva
groups of C
 H5N1 subv
 A/Vietnam
3 µg of H5N
inal center B
er of non-si
 standard err
creased affin
nted H5N1 
57BL/6 wild
irion vaccin
/1203/2004 
1 subvirion
-cells in spl
lent mutatio
or. 
ity maturat
vaccines. 
-type mice 
e (MF59-, a
(H5N1) infl
 vaccine in P
eens five da
ns within th
41 
ion of the B
(n=5) were 
lum-adjuvan
uenza virus 
BS. (A) Sh
ys after the 
e IGHV gen
-cell respons
intramuscul
ted or unad
infection. A
own are abs
last booster 
es. ns, not s
es mediated
arly primed 
juvanted) or
ll groups w
olute numbe
immunizati
ignificant. E
 
 by alum- 
either with 
 with sub 
ere boosted 
rs of the 
on. (B) Mea
rror bars 
1 
n 
42 
 
To determine the extent of affinity maturation in the responding B-cells, we 
sorted antibody forming cells (AFCs) from the draining (inguinal) lymph nodes by flow 
cytometry (CD4neg, CD8neg, IgDneg, B220low and CD138pos cells) and total RNA was 
isolated. More than 80% of the IgG producing cells were specific to H5 by Elispot assay 
(not shown). Next, the cDNA was used as a template to amplify the immunoglobulin 
heavy chain variable (IGHV) genes. The PCR amplicons were sequenced by using the 
454 deep sequencing (see Materials and Methods). Additionally, a group of mice that 
were immunized once with the unadjuvanted vaccine was included. We observed that 
similar to the infection group, including alum and MF59 adjuvants in the priming 
immunization enhanced affinity maturation of the recalled B-cell response compared to 
priming with the unadjuvanted vaccine (Fig. 3-2B). 
 
 
Similar Binding Pattern by Adjuvanted and Unadjuvanted H5 Immune 
Serum-Derived IgGs to H5 HA Antigen Microarray 
 
 After establishing that adjuvanted H5N1 vaccines elicited quantitatively greater 
H5-specific antibody titers than the unadjuvanted vaccine preparation, we wanted to 
further explore differences in quality by considering the range of target specificity 
induced by each priming regimen. We tested whether there are differences in the 
specificity of binding to linear epitopes of the H5 HA protein. To this end we constructed 
H5 antigen microarrays using 54 peptides that span the full length of H5 HA of 
A/Vietnam/1203/2004 (H5N1). The peptides are 18mers with 10 amino acids overlap and 
were spotted on epoxy glass slides as described in the materials and methods section. IgG 
(normalized to equal IgG content) immunoglobulins purified from sera derived from 
mice immunized with H5N1 vaccine either adjuvanted (with alum or MF59) or 
unadjuvanted that were normalized and their binding to the H5 antigen chip was tested. 
There was minimal binding shown by IgGs purified from sera derived from naïve mice 
(Fig. 3-3).  The pattern of binding of IgGs from the different groups, indicated by the 
identity of peptides targeted, was similar (Fig. 3-3). These peptides were, however, 
targeted to different extents among the 4 groups (Fig. 3-3). These data indicate that, at 
least for H5 linear epitopes, the composition of the responses elicited by the adjuvanted 
and unadjuvanted vaccines to such epitopes is similar, but with apparent variation in 
epitope immundominance.  
 
 
Similar Inhibition Pattern by Adjuvanted and Unadjuvanted H5 Immune Sera by 
H5 Monoclonal Antibodies 
 
A major limitation of the H5 antigen microarray is that it only examines the 
binding to linear epitopes. It is assumed that many of the neutralizing antibody epitopes 
on HA are conformational in nature. Therefore, we next examined the binding of the sera 
from the different groups to epitopes in the globular head of HA. We used a competitive 
ELISA approach with human monoclonal antibodies (mAbs) that recognize the globular 
head and measured their capacity to inhibit the binding of these sera. The binding of the 2 
mAbs, 10C3 and 7H5, was mapped to amino acid residues within the globular head of  
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the H5 HA. 10C3 binding was mapped to the amino acid residue 145 which lies in 
antigenic site 1 of H5 HA (29) and 7H5 binds to the amino acid residues 154 and156 
which represent antigenic site 2 of H5 HA (29). ELISA plates were coated with 
recombinant H5 HA (A/Vietnam/1203/04) and incubated with or without an excess of the 
human mAbs followed by addition of mice sera at a dilution that gives 70-80% of 
maximum binding to all plates that were then detected using mouse-specific secondary 
reagents. We found that binding of the sera from the four groups was inhibited to similar 
extent by the two mAbs (Fig. 3-4A-B). This indicates that the proportions of antibodies 
targeting the epitopes blocked by these 2 mAbs among the different sera groups are 
equivalent (Fig. 3-4A-B) and that the response to these epitopes is a substantial 
population of the overall response. 
 
 
Discussion  
 
 While the use of vaccines to protect humans against infectious diseases has been 
introduced over two centuries ago, only a few adjuvants are currently licensed for use in 
humans. In the context of influenza vaccines, this is partially because vaccines were 
traditionally formulated as whole inactivated viruses, which are strongly immunogenic. 
Currently, inactivated influenza vaccines are mostly formulated as split or subunit 
vaccines, which mainly contain purified HA and NA. While these subunit preparations 
have induced minimal adverse reactions, they displayed poor immunogenicity in clinical 
trials (78). The use of adjuvants with subunit vaccines has significantly boosted the 
immunogenicity of such vaccines (69). While the quantitative outcome of including 
adjuvants with influenza vaccines is well documented, the impact of these adjuvants on 
the quality of immune response to influenza vaccines is still unclear. Therefore, it is 
becoming increasingly important to determine how clinically relevant adjuvants such as 
alum and MF59 modulate the immune responses to influenza vaccines.  More 
specifically, we examined whether or not including adjuvants induces a broader response 
to influenza vaccines compared to unadjuvanted preparations. Our data clearly show that 
MF59-adjuvanted H5N1 vaccines elicits a quantitatively greater H5-specific antibody 
response than the alum-adjuvanted or the unadjuvanted vaccine. These titers were 
consistent with the ability of MF59-adjuvanted vaccine to prime for more robust 
H5-specific B-cell responses numerically, generating greater numbers of germinal center 
B cells. However, for the most part, the specificity of these antibodies was not different 
than induced by alum or vaccine alone as determined by and H5 antigen microarray. 
Additionally, competitive inhibition studies using antibodies that target prominent 
epitopes on the HA globular head indicated that these epitopes were targeted to a similar 
extent. It is important to note that although the alum-adjuvanted vaccine responses were 
inferior to those induced by MF59, the activated B-cells showed an equivalent degree of 
maturation.  Our results may appear to contrast previous reports, which suggested that 
including MF59 with H5N1 and seasonal influenza vaccines enhance antibody titers to 
drifted (from the vaccine parent strain) virus strains (88, 93-95). Moreover, Khurana and 
colleagues have tested the binding pattern of sera obtained from H5N1 vaccine clinical 
trials using influenza-specific whole-genome fragment phage display libraries and 
concluded that the use of MF59 expanded the number of epitopes targeted when  
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combined with H5N1 vaccines (59). The explanation for these discrepancies may be 
explained in light of two factors: 1) the assay used to estimate cross-reactivity is the 
hemagglutination inhibition (HI) assay. HI is the standard assay used in evaluating the 
efficacy of influenza vaccines and it detects antibodies that block receptor binding. The 
sensitivity of the assay is low, which in turn may result in overlooking antibody 
responses to sub-dominant epitopes in the case of unadjuvanted vaccine responses. With 
the MF59-adjuvanted responses, however, the immune response is greatly enhanced to 
antibody levels targeting these sub-dominant epitopes exceeding the assay detection 
limit. Overall though, the target specificities are shared. 2) MF59-adjuvanted vaccines 
activate antigen-specific memory CD4+ T-cells to a greater extent compared to the 
unadjuvanted preparations (102). This activation might have led to a greater involvement 
of pre-existing memory B-cell populations upon immunization. In support of this notion 
is that in contrast to our studies with naïve mice, the data from which the adjuvant 
induced “breadth” of antibody responses assumption was derived come mainly from 
clinical trials. Therefore, the observed specificity differences between the adjuvanted and 
unadjuvanted responses may stem from that humans have pre-existing specificities that 
an unadjuvanted vaccination may not be able to generate. 
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CHAPTER 4.    INFLAMMASOME-INDEPENDENT ROLE OF THE 
APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN CONTAINING CARD 
(ASC) IN THE ADJUVANT EFFECT OF MF592 
 
 
Introduction 
 
The primary means of infection- and vaccine-mediated immunologic protection 
against influenza A viruses (IAVs) is the development of antibodies that bind and 
neutralize the receptor binding function of hemagglutinin (HA). Vaccination is the most 
efficient means to minimize influenza-mediated illness. However, the results from the 
first clinical trials of unadjuvanted subunit H5N1 vaccines were disappointing in terms of 
immunogenicity (78). Substantial improvements have, however, been seen in trials with 
the adjuvanted formulations specifically using the new generation oil-in-water 
emulsion-based adjuvants that have induced significantly higher antibody responses to 
low antigen-content vaccines (69).  
 
The main licensed adjuvants used with influenza vaccines such as alum and MF59 
have been empirically developed. The molecular mechanism of these two adjuvants is 
still largely undefined. It has been shown that alum and MF59 induce the secretion of a 
range of cytokines associated with recruitment of innate immune cells to the injection site 
(99, 103, 104). The immunostimulatory activity of alum has been, at least in part, 
attributed to the ability of alum to activate an innate immune sensor that belongs to the 
NOD-like receptors (NLRs) family (64). NLRs are a large family of intracellular proteins 
that are believed to be primarily involved in the innate immune response to microbial 
pathogens through the recognition of conserved pathogen-associated molecular pattern 
(105). However, they also contribute by sensing “danger signals,” i.e., endogenous 
molecules that are produced during tissue damage or inflammation (105). Specifically, in 
NLR-Pyrin domain containing 3- (NLRP3) deficient mice, decreased IL-1β secretion and 
antigen-specific humoral immune responses to immunization with alum-adsorbed 
antigens have been observed (106, 107).  
 
NLRP3 allows for the recruitment and autocatalytic activation of the cysteine 
protease caspase-1 in a large cytosolic protein complex named the “inflammasome” 
(108). Once activated, the inflammasome mediates caspase-1 cleavage of the inactive 
precursor of the proinflammatory cytokine, IL-1β, resulting in release of mature IL-1β. 
The adapter protein ASC bridges the interaction between NLRP3 and the caspase-1, 
making it essential for activation of the inflammasome (108). Whether or not any of the 
NLRP3 inflammasome components (NLRP3, ASC, and caspase-1) play a role in 
MF59-mediated immune stimulation has not been addressed. The goal of this study was 
to understand the role of the different NLRP3 inflammasome components (NLRP3, ASC, 
and caspase-1) in MF59-mediated immune stimulation. 
                                                 
 
2 This chapter was adapted with permission. A. H. Ellebedy et al., Proc Natl Acad Sci U S 
A 108, 2927 (Feb 15, 2011) (120). 
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Materials and Methods 
 
 
Mice and Immunization 
 
 Cryopyrin/Nlrp3-/-, ASC-/-, and caspase-1-/- mice were backcrossed to a C57BL/6 
background for at least 10 generations. Mice were housed in a pathogen-free facility, and 
the animal studies were conducted under protocols approved by the St. Jude Children’s 
Research Hospital Committee on Use and Care of Animals. Animals were immunized 
intramuscularly twice with 1, 3, or 5 μg of monovalent H5N1 influenza 
(rgA/Vietnam/1203/2004) subvirion vaccine (Aventis Pasteur Inc., Swiftwater, PA) 
either unadjuvanted (in PBS), mixed with MF59 (1:1) or adsorbed to aluminium 
hydroxide at 14.1 mg/ml Alum, 3 μg/ml antigen and 5 mM Histidine buffer pH 6.5 at 4°C 
overnight. Incomplete Freund’s adjuvant or IFA (Sigma, St. Louis, MO) was mixed with 
the vaccine solution in 1:1 (v/v) ratio and emulsified just before injection. Each mouse 
dose contained 500 μg Alum. The intranasal infections were performed with 100 egg 
infectious dose 50 of the rgA/Vietnam/1203/2004 (Δ HA) diluted in PBS to a final 
volume of 30 µl. 
 
 
Hemagglutination Inhibition Assay 
 
PBS containing four agglutinating units of A/Vietnam/1203/2004 (H5N1) virus 
was incubated with serial 2-fold dilutions of RDE-treated serum samples (starting at a 
1:10 dilution) at room temperature for 30 minutes. The HI titers of the samples were 
determined by testing agglutination of 0.5% of chicken red blood cells. 
 
 
Elispot Assay 
 
Ninety-six-well nitrocellulose-bottomed multiscreen HA filtration plates 
(Millipore, Billerica, MA) were coated (0.1 μg/well) with H5 protein of the 
A/Vietnam/1203/2004 (H5N1) virus (e.Enzyme, Montgomery Village, MD). After 
overnight incubation at 4°C, the plates were washed with PBS and subsequently blocked. 
Next, different dilutions of bone marrow cell suspensions were added in volumes of 100 
μl/well. After 4 hours of incubation at 37°C in a humidified atmosphere containing 5% 
CO2, the plates were washed with PBS, and alkaline phosphatase-conjugated goat 
anti-mouse IgG (SouthernBiotech, Birmingham, AL) diluted in PBS containing 5% 
bovine serum albumin was added (100 μl/well) and incubated overnight at 4°C. Spots 
were developed by adding 100 μl/well of BCIP/NBT phosphatase substrate (Kirkegaard 
& Perry Laboratories, Gaithersburg, MD), then counted with an Olympus SZX9 
stereozoom microscope for analysis using KS Elispot software (Zeiss, Thornwood, NY). 
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Enzyme-Linked Immunosorbent Assay (ELISA) 
 
In brief, microtiter plates (Corning Inc., Corning, NY) were coated overnight at 
4°C (0.1 μg/well) with H5 protein of the A/Vietnam/1203/2004 (H5N1) virus (e.Enzyme, 
Montgomery Village, MD). Plates were then washed with PBS containing 0.05% Tween 
20 and subsequently blocked. Influenza-specific antibody responses were detected with 
goat anti-mouse IgM, IgG, IgG1, IgG2b, IgG2c, IgG3, or IgE conjugated to alkaline 
phosphatase (SouthernBiotech, Birmingham, AL). A substrate (p-nitrophenyl phosphate; 
Sigma-Aldrich, St. Louis, MO) was added, plates were incubated for 30 minutes at room 
temperature for color development, and optical density values were determined at 405 nm 
in an ELISA reader (Molecular Devices, Sunnyvale, CA). Titers were presented as the 
highest dilution that yielded an optical density three times greater than that of a 1/100 
dilution of pre-immune serum. Serum IgG levels were determined using a mouse IgG 
ELISA kit (Life Diagnostics, West Chester, PA). 
 
 
Flow Cytometry 
 
Mice were euthanized via CO2  inhalation and inguinal lymph nodes were 
harvested after immunization. Lymph nodes were manually disrupted by grinding organ 
tissue between the frosted ends of two sterile glass microscope slides in sterile PBS 
containing 2% fetal bovine serum. Cells were then labeled with anti-CD16/CD32 (clone 
2.4G2, BD PharMingen, San Diego, CA) to block nonspecific Fc receptor-mediated 
binding. After washing, cells were stained with different combinations of fluorescently 
labelled antibodies against CD8α (clone 53-6.7, BD PharMingen), CD4 (clone RM4-5, 
BD PharMingen), CD11b (M1/70, Biolegend, San Diego, CA), IgD (11-26c.2a, BD 
PharMingen), CD138 (281-2, BD PharMingen), B220 (RA3-6B2, BD PharMingen), FAS 
(Jo2, BD PharMingen), and GL7 (BD PharMingen). Labeled cells were assayed with a 
FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ) and data were 
analyzed using FlowJo (Tree Star, Ashland, OR) software. 
 
 
Generation and Analysis of Bone Marrow-Derived Dendritic Cells 
 
BMDC cultures were prepared as described previously (109) and stimulated with 
MF59 (1:100 V/V) or as indicated in the figure legends for 24 hours. Cell culture 
supernatants were harvested, and the different cytokines were assayed using Milliplex 
Map kits (Millipore, Billerica, MA). 
 
 
Statistical Analysis 
 
Statistical analyses were performed using InStat (GraphPad, La Jolla, CA) 
software. In most cases, the Mann-Whitney (non-parametric) test was used to compare 
results. 
 
50 
 
Results 
 
 
The Humoral Immune Response to MF59-Adjuvanted Vaccines Requires ASC but 
Not NLRP3 or Caspase-1 
 
NLRP3 inflammasome has been implicated in the adjuvant effect of alum. 
Therefore, we asked whether the NLRP3 inflammasome plays any role in mediating the 
adjuvant activity of MF59. We first determined the hemagglutination inhibition (HI) 
titers of WT, NLRP3-/-, ASC-/-, and caspase-1-/- mice after vaccination with 
MF59-adjuvanted H5N1 subvirion vaccine. We found that ASC-/- mice, but not NLRP3-/- 
or caspase-1-/- mice, elicited significantly lower HI titers than WT mice (Fig. 4-1A). We 
next determined the serum levels of the different H5-specific antibody isotypes in 
immunized mice 3 weeks after a booster immunization. Consistent with the HI results, 
circulating levels of H5-specific IgM, IgG, IgG1, IgG2b, and IgG2c antibodies were 
comparably elevated in the serum of WT, NLRP3-/-, and caspase-1-/- mice (Fig. 4-1B-F). 
Immunized ASC-/- mice, however, elicited significantly less IgG, IgG1, IgG2b, and 
IgG2c antibodies than WT mice (Fig. 4-1C-F). Interestingly, circulating levels of 
H5-specific IgM antibodies in ASC-/- mice were comparable to those of WT mice (Fig. 
4-1B). 
 
As a control, we examined the H5-specific antibody response to the unadjuvanted 
vaccine in WT, NLRP3-/-, ASC-/- and caspase-1-/- mice (Fig. 4-2A). ASC-/- mice robustly 
responded to the unadjuvanted vaccine indicating that the defective response observed 
with the MF59-adjuvanted vaccine was not due to a general defect in these mice to this 
particular inactivated influenza vaccine. In addition, infection with a sublethal dose of an 
attenuated H5N1 virus resulted in comparable ant-H5 IgG titers in WT and ASC-/- mice 
as measured three weeks post infection (Fig. 4-2B). We next tested the antibody response 
to H5N1 vaccine adjuvanted with incomplete Freund’s adjuvant (IFA) in WT and. ASC-/- 
mice. Again, there were no significant differences in H5-specific IgG1 or IgG2c antibody 
titers (Fig. 4-2C-D). These results suggested that ASC is specifically required for the 
optimal generation of antigen-specific antibodies in response to MF59-adjuvanted H5 
vaccines. In addition, class switching anti-H5 antibodies from IgM to IgG rather than 
antibody production itself was impaired in ASC-/- mice.  
 
 
ASC Is Required for Germinal Center B-Cell Formation after Immunization with 
MF59-Adjuvanted Vaccines 
 
Antibody class switching after vaccination or infection takes place mainly within 
the germinal center (GC) reaction in the draining lymph nodes (100). The observed 
decrease in IgG production in ASC-/- mice after MF59-adjuvanted H5N1 vaccination 
suggested a defect in the development of the GC reaction in these mice. To investigate 
this possibility, we immunized WT, NLRP3-/-, ASC-/-, and caspase-1-/- mice with the 
MF59-adjuvanted H5N1 vaccine and harvested the draining (inguinal) lymph nodes as 
well as sera 7 days later. 
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H5-specific IgM and IgG antibodies were undetectable in the sera of ASC-/- mice, 
whereas both isotypes were detectable in the other three groups (Fig. 4-3A-B), indicating 
a delay in the induction of the antibody response in the ASC-/- mice. In agreement with 
this, WT, NLRP3-/-, and caspase-1-/- mice all had significantly larger lymph nodes than 
ASC-/- mice, as evidenced by the difference in cellularity (Fig. 4-3D). We next looked at 
the frequency of GC B-cells in the draining ipsilateral lymph nodes. GC B-cells were 
defined by flow cytometry lymphocytes with the following expression profile; negative 
for surface CD4, CD8, and CD11b with low expression of surface IgD and high surface 
expression of B220 and FAS (CD195). We found that in WT, NLRP3-/-, and caspase-1-/- 
mice, GC B-cells were comparably developed, accounting for 30-50% of the B220+ 
B-cell population (Fig. 4-3C&E). On the other hand, GC B-cell frequencies in the ASC-/- 
mice were significantly lower (Fig. 4-3D&E).  
 
The generation of a GC B-cell reaction requires the help of CD4+ T-cells, so we 
asked whether they exhibited similar defects. Indeed, we found that absolute numbers of 
CD4+ T-cells in the ASC-/- mice were significantly lower than in WT mice (Fig. 4-3F). 
These results show that ASC, independent of the caspase-1 inflammasome, is required for 
the rapid induction of the antibody response to MF59-adjuvanted H5N1 vaccines. 
Moreover, the development of a GC reaction in the draining lymph nodes of ASC-/- mice 
is impaired, explaining the defect observed in antibody isotype switching in these mice. 
This defect was not B-cells specific as CD4 T-cell frequencies were significantly lower in 
ASC-/- mice, potentially contributing to the germinal center phenotype. 
 
 
ASC Is Required for Robust Antigen-Specific Recall B-Cell Responses 
 
The ultimate outcome of a GC B-cell reaction is the generation of high–affinity, 
antigen-specific memory B-cells and long-lived plasma cells (PCs) (100). Upon antigen 
re-exposure, memory B-cells rapidly expand and differentiate into antibody-forming cells 
(AFCs). We therefore investigated whether the defect in GC B-cell development 
observed in ASC-/- mice after priming would, in turn, result in a defective H5-specific 
memory B-cell compartment. To test that, we primed WT, NLRP3-/-, ASC-/-, and 
caspase-1-/- mice with one dose of MF59-adjuvanted H5N1 vaccine, and all mice were 
given a booster with the same vaccine in PBS 3 weeks later. Similar to our observations 
with the primary response, 5 days after antigen re-exposure, WT, NLRP3-/-, and 
caspase-1-/- mice had significantly larger draining lymph nodes than ASC-/- mice, and that 
was mirrored by a greater number of live cells (Fig. 4-4A). Also, GC B-cell numbers 
were significantly lower (Fig. 4-4B). Moreover, the number of CD138+ PCs in ASC-/- 
mice was significantly lower than in WT, NLRP3-/-, and caspase-1-/- mice (Fig. 4-4C). In 
agreement with the decreased number of CD138+ cells in ASC-/- mice after the boost, the 
number of H5-specific AFCs in the bone marrow was similarly lower (Fig. 4-4D). When 
we compared the IgG antibody titers in mice sera before and five days after the boost, 
ASC-/- mice showed a slight (2-fold) increase in antibody titer (Fig. 4-4E). In contrast, 
WT, NLRP3-/-, and caspase-1-/- mice showed a significantly larger (5- to 6-fold) increase 
in H5-specific IgG titers after the boost, signifying a robust memory response in these 
mice (Fig. 4-4E).  
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Figure 4-3. Defective germinal center B-cell development in ASC-/- after 
immunization with MF59-adjuvanted H5N1 subvirion vaccine. 
 
C57BL/6 wild type, Nlrp3-/-, ASC-/- and caspase-1-/- mice immunized with 5 µg of H5N1 
subvirion vaccine adjuvanted with MF59. Serum and draining (inguinal) lymph nodes 
were collected 7 days after immunization. Mean circulating levels of H5-specific (A) IgM 
and (B) IgG antibodies were determined as in Fig. 4-1. (C), Representative FACS plots 
for lymphocytes from the draining lymph nodes stained with monoclonal antibodies to 
B220 and CD95 (FAS) on day 7 after immunization with 5 µg of H5N1 subvirion 
vaccine adjuvanted with MF59. The gated population (circled in red) from each plot 
represents germinal center B-cells, which were defined as cells that were negative for 
surface CD4, CD8, and CD11b with low expression of surface IgD and high surface 
expression of B220 and FAS (CD195). (D), Mean number of live cells in the ipsilateral 
draining lymph node. (E) Total number of germinal center B-cells as determined by 
FACS analysis of the cells with the phenotype defined in (C). (F), Total number of CD4+ 
lymphocytes. Statistically significant differences between WT and mutant groups are as 
indicated with asterisks; *, p<0.05. Error bars show standard error.
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These results demonstrate that ASC is required for the optimal priming of 
antigen-specific B-cell memory responses with MF59-adjuvanted vaccines. 
 
 
ASC Expression in Dendritic Cells Is Required for Adequate Production of 
Inflammatory Cytokines 
 
We have shown that ASC-deficiency results in poor B and CD4 T cell responses 
to MF59-adjuvanted H5N1 subvirion vaccines. To further elucidate the mechanism by 
which ASC acts we started from the knowledge that the adjuvant effect of MF59 and 
alum at least partially depends on their ability to induce the secretion of chemokines 
responsible for recruiting inflammatory cells to the site of injection (103). It has been 
shown that within 48 hours of MF59 intramuscular injection, Dendritic cells or DCs 
internalize most of the adjuvant (72). We therefore investigated whether the defective 
antigen-specific antibody response in immunized ASC-/- mice was due to a defective 
inflammatory response by bone-marrow derived dendritic cells or BMDCs. To examine 
this, BMDCs from WT, NLRP3-/-, ASC-/- and caspase-1-/- mice were incubated with 
MF59 and the secretion of proinflammatory cytokines in the culture supernatant was 
determined. For proinflammatory cytokines such as MIP1b and MIP2, WT BMDCs 
secreted significantly (p= 0.002 and 0.005, respectively) more as compared to BMDCs 
derived from ASC-/- but not significantly more than those derived from NLRP3-/- and 
caspase-1-/- mice (Fig. 4-5A-B). 
 
These results suggest that the inflammasome-independent role of ASC in 
generating the proper inflammatory environment after immunization may be the 
underlying cause of the defective induction of humoral immunity in the ASC-deficient 
mice. 
 
 
Discussion 
 
 Unadjuvanted split and subunit H5N1 vaccines have been reproducibly shown to 
be poorly immunogenic in humans (78). The addition of alum adjuvant induced only 
marginal improvements (69). In contrast, oil-in-water based adjuvants (e.g., MF59) have 
been shown to prime for a robust and broadly cross-reactive antibody response to 
subvirion H5N1 vaccines with greatly reduced antigen requirements (69). MF59 has 
shown encouraging results in several influenza formulations and is licensed for use in 
seasonal influenza vaccines in Europe (74). However, the mechanism underlying the 
ability of MF59 and other adjuvants to stimulate the immune system remains poorly 
understood. In order to develop more defined next generation adjuvants, it is critical to 
determine the immunologic processes that are stimulated by MF59 and other efficacious 
adjuvants. Recent studies have shown that induction of antigen-specific antibody 
responses by commonly used vaccine adjuvants, such as alum and Freund’s complete and 
incomplete adjuvants did not require signaling through Toll-like receptors (110). 
However, the ability of alum and other particulate adjuvants to enhance IL-1 secretion via  
NLRP3 has been described (107). 
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In addition, some studies have shown that enhancement of antigen-specific 
humoral immunity by alum was also NLRP3-dependent (64), although later reports 
suggested that NLRP3 was not required (65, 66). Here, we found that the antibody 
response to H5N1 subunit influenza vaccines adjuvanted with MF59 critically depend on 
the presence of the adapter molecule ASC. After immunization with MF59-adjuvanted 
H5N1 subvirion vaccines, the amount of H5-specific antibodies of IgG1, IgG2b, and 
IgG2c subtypes were all significantly lower in ASC-/- mice than in WT mice. In contrast 
to studies with alum, we found that neither NLRP3 nor caspase-1 was required for the 
antigen-specific antibody responses to MF59-adjuvanted H5N1 influenza subvirion 
vaccines, indicating that the proposed role of ASC is independent of the caspase-1 
inflammasome. It is interesting to note, however, that the murine antibody response to 
antigens emulsified in Freund’s complete adjuvant has been shown to be unaffected by 
the absence of ASC (64). This suggests that even among emulsion-based adjuvants, the 
molecular requirement for the proper induction of an adaptive immune response varies. It 
is also possible that the complex nature of Freund’s complete adjuvant affords immune 
stimulation through a number of redundant mechanisms. 
 
Complexities of the response to adjuvants aside, our data support recent findings 
in the murine model of collagen-induced arthritis as well as in the development of 
experimental autoimmune encephalomyelitis that show an inflammasome-independent 
role for ASC in the induction of various forms of immunity and immunopathology (111, 
112). There are several molecular mechanisms by which ASC may control the 
antigen-specific antibody response to MF59-adjuvanted vaccines. A key underlying 
feature in the ASC-/- mice was the significantly reduced production of key inflammatory 
cytokines by BMDCs as compared to WT derived cells after stimulation with MF59. 
Consistent with a defect in antigen presenting cells, it has been suggested that 
antigen-specific activation of T-cells by ASC-deficient BMDCs was significantly 
impaired (112). In line with this notion, after a single immunization with 
MF59-adjuvanted H5N1 vaccine, we observed a delayed antigen-specific antibody 
response and significantly lower numbers of CD4+ T-cells in the draining lymph nodes 
vaccine in ASC-/- but not NLRP3-/- or caspase-1-/- mice in comparison to their WT 
counterparts. In humans, the early development of an antigen specific CD4+ T-cell 
response was shown to be a successful predictor of the robustness and persistence of an 
antibody response following MF59-adjuvanted H5N1 vaccination (102). We also 
demonstrated that the development of GC B-cells in the draining lymph nodes was 
significantly impaired in ASC-/- mice in comparison with that seen in WT, NLRP3-/-, and 
caspase-1-/- mice after immunization. In addition, we showed that these defects resulted 
in a poor memory B-cell response in ASC-/- mice.  
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CHAPTER 5.    GENERAL CONCLUSIONS, LIMITATIONS AND FUTURE 
DIRECTIONS 
 
 
Prophylactic vaccination is based on a central feature of the adaptive immune 
system, immunological memory (113). Immunological memory represents the ability of 
the immune system to mount a robust recall response upon reexposure to a previously 
encountered antigen. The traditional microbial vaccines, live attenuated or whole 
inactivated pathogens, are strongly immunogenic due to their microbial content. 
However, the toxicity and risks associated with some of these preparations engendered 
the necessity to develop safer vaccines such as the purified protein preparations (114). 
The major challenge with these subunit protein vaccines is their poor immunogenicity. In 
order to efficiently design protein vaccines that stimulates protective immune responses, 
two factors must be considered; the choice of the antigen to be included in the vaccine 
preparation and the ability to stimulate the innate immune system. In the context of 
influenza vaccines, HA is clearly the antigen of choice because anti-HA antibodies can 
block the initiation of viral infection (45). As for the innate immune stimulation, the 
major advance achieved in this regard was the introduction of Adjuvants (60). 
 
The word adjuvant is derived from the Latin word adjuvare, which means to aid 
(60). Adjuvants represent chemically and structurally diverse compounds. Traditionally, 
the use of adjuvants was primarily to enhance the quantitative immune response to 
vaccine antigens. For influenza vaccines, the benefits of adding adjuvants have been well 
documented (60). Basically, adjuvants increase the antibody titers in response to 
influenza vaccines in the general population and in individuals where the immune system 
is compromised. However, modulating the quality of the immune response has become 
an increasingly important aspect of the impact of adjuvants on vaccines in general. There 
are several factors through which adjuvants can possibly fine tune the immune responses 
to influenza vaccines; increasing the speed of the protective immune response, which is 
an essential measure in the event of an influenza pandemic; boosting the memory 
immune response, which provides a robust recall response upon reexposure; increasing 
the affinity of the HA-specific antibodies to increase the efficiency of virus 
neutralization; and increasing the breadth of the antibody response, which is important to 
generate cross reactive antibodies. A final quality that adjuvants can impart to the 
immune response to influenza vaccines is their ability to activate the most appropriate 
effector molecules. For example, among the different antibody isotypes, stimulating the 
secretion of IgA or IgG2a/c is arguably the most efficient in achieving protection (115).  
 
Despite the fact that vaccines were introduced over two centuries ago, very few 
adjuvants have been licensed to be used with human vaccines (62). Over the past several 
decades many vaccine adjuvants, such as Freund’s complete and incomplete adjuvants, 
have been tested and shown to be highly efficient in stimulating strong immune responses 
(62). The toxicity of these adjuvants, however, has limited their use with human vaccines 
(62). Currently, adjuvants that are licensed for use with human influenza vaccines were 
empirically developed. These adjuvants have been shown to be efficient and safe (60). 
The molecular details of the mechanisms mediating the adjuvanticity of clinically 
61 
 
licensed adjuvants are still largely undefined (99). It is clear that dendritic cells (DCs) 
represent the most common target of many of these adjuvants. Effects of adjuvants on 
DCs vary from stimulating their migration, maturation, ability to present antigens to 
cytokine secretion. In order to be able to develop new or better adjuvants, the current 
adjuvants need to be mechanistically investigated. Over the past decade, many advances 
have been achieved in defining the molecular details of key pathways of the innate 
immune system. These discoveries have opened the door for scientists to explore the 
possible contribution of the innate immune system to the adjuvanticity of existing 
adjuvants.   
 
Since their emergence in 1996, highly pathogenic H5N1 influenza viruses have 
evolved into at least 10 phylogenetically and antigenically different clades and multiple 
subclades (77). They pose a continuous threat of an influenza pandemic. Despite still 
being rare incidents, the mortality rate associated with human infections with these 
viruses is estimated to be 50-60% (77). This situation has been the catalyst for an increase 
in the amount of resources applied to preparedness activities for such a pandemic. 
Vaccine development has been the main focus of these activities. However, vaccine 
formulation has been a major challenge because these vaccines are not only required to 
effectively prime a population immunologically naïve to H5 antigens but also to protect 
against a broad spectrum of rapidly evolving viruses. This is because it is not known to 
which clade or subclade the potential pandemic H5N1 virus would belong to. The 
majority of the stockpiled pre-pandemic H5N1 vaccines are derived from clade 1 viruses 
(http://www.who.int/csr/disease/avian_influenza/guidelines/H5VaccineVirusUpdate2008
0214.pdf). Clinical trials indicated that compared to seasonal human influenza vaccines, 
H5N1 influenza vaccines elicit lower antibody titers at comparable antigen doses (78). 
Although currently there are no adjuvanted vaccines against seasonal influenza viruses 
licensed in the US, the poor immunogenicity of subvirion H5N1 influenza vaccines 
introduced the necessity of including adjuvants in the vaccine formulation. 
 
 
Adjuvants Enhance the Kinetics of Protective Antibody Responses to H5N1 
Influenza Vaccines 
 
In Chapter 2, I investigated the impact of adjuvants on the speed of the immune 
response to pre-pandemic H5N1 influenza vaccines in the ferret model. The vaccine used 
was the subunit vaccine derived from A/Vietnam/1194/2004 (H5N1) and the adjuvants 
used in the study were MF59 and alum. Ferrets were immunized with vaccine in PBS or 
mixed with either of the two adjuvants at different time points prior to lethal challenge 
with A/Vietnam/1203/2004 (H5N1). We found that including an adjuvant in the vaccine 
formulation was essential for protection against lethality. This protection was, at least 
partially, attained when immunized ferrets were challenged as early as 7 days post 
immunization. This protection was lost when the pre-challenge incubation period was 
reduced to 4 days. Expectedly, extending this period to 14 or 21 days led to full 
protection against lethality and challenge associated morbidity. It is interesting to note 
that we were not able to detect H5 specific antibodies either by HI or ELISA in the sera 
of ferrets that survived after lethal challenge. 
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Implications and Limitations 
 
The general human population is immunologically naïve to H5N1 and other avian 
influenza viruses such as H7N7 and H9N2 as well. If an H5N1 avian influenza pandemic 
is to start soon, the first lines of defense would be antiviral drugs and stockpiled 
pre-pandemic vaccines. As for the antiviral drugs, assuming that the emerging virus 
retains the susceptibility for these drugs, the mass demand expected is very unlikely to be 
met by the existing stocks, which will be quickly depleted. The stockpiled pre-pandemic 
influenza vaccines would, therefore, play a crucial role in the response to any emerging 
epidemic and pandemic. Indeed, researchers, using mathematical modeling, have 
predicted that pre-pandemic vaccines when utilized at the early stages of the pandemic 
would significantly limit the virus spread (84, 116). The protection would even be greater 
when other measures such as social distancing and travel restriction are applied. These 
theoretical studies are assuming that it would take at least 2 immunizations and 14 days 
post-immunization to attain full protection from lethality. Our data show that the 
protection can be attained in a shorter period (7 days) after a single immunization, which 
in turn means that a more efficient control of any emerging influenza pandemic can be 
achieved using adjuvanted pre-pandemic vaccines.   
 
 The poor immunogenicity displayed by the unadjuvanted pre-pandemic H5N1 
vaccines puts into question the suboptimal utilization of adjuvants in the context of such 
vaccines. The two adjuvants used in the study are both licensed to be used in human 
influenza vaccines. Several studies have indicated that alum is inferior to water-in-oil 
emulsion based emulsions such as MF59 in inducing strong antibody response to 
influenza vaccines. These conclusions were derived from clinical studies or pre-clinical 
studies performed in mice. In our studies, however, alum has shown an equivalent, if not 
superior, ability to induce a protective antibody response to the H5N1 subunit influenza 
vaccine. The difference in the animal model used may be the reason for what we 
observed.  
 
 The challenge virus we used in our study is antigenically indistinguishable from 
the vaccine parent strain i.e. homologous challenge. This is most likely will not be the 
case and therefore the protection observed will largely depend on how antigenically 
distant the vaccine parent strain from challenge virus strains.  
 
 
Future Directions  
 
 While showing that a single immunization with an adjuvanted pre-pandemic 
H5N1 vaccine can provide protection against lethality in a relatively short period (7 days) 
is important, it will be equally essential to determine how long such protection would 
last. Also, it will be important to determine whether this protection will block virus 
transmission.  
 
 Germann and colleagues have predicted that even the use of a poorly matched 
pre-pandemic vaccine would be helpful in the containment plans in the event of an 
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influenza pandemic (84). Their rational was that this poorly matched vaccine could slow 
virus spread as much as possible until a well matched vaccine based on the emergent 
human pandemic virus could be deployed. Therefore, it will be important to determine 
the extent of protection, if any, that can be achieved in the heterologous challenge 
scenario.  
 
 
Adjuvants’ Impact on the Breadth of the Antibody Responses to Subunit H5N1 
Influenza Vaccines 
 
In Chapter 3, I studied the impact of the adjuvants MF59 and alum on the breadth 
of the antibody responses to subunit H5N1 vaccines.  The results showed that 
MF59-adjuvanted H5N1 vaccines elicits a quantitatively greater H5-specific antibody 
response than the alum-adjuvanted or the unadjuvanted vaccine. These titers were 
consistent with the ability of MF59-adjuvanted vaccine to prime for more robust 
H5-specific B-cell responses. However, the specificity of these antibodies was not 
different. Using H5 antigen microarray, the binding pattern of purified IgG 
immunoglobulins from mice immunized with MF59- or alum-adjuvanted or the 
unadjuvanted vaccine was similar. Additionally, competitive inhibition studies using 
antibodies that target prominent epitopes on the HA globular head indicated that these 
epitopes were targeted to a similar extent. 
 
 
Implications and Limitations 
 
 The primary challenging issue with influenza vaccines in general is that their 
efficacies drop as the circulating virus evolves away from the vaccine parent strain itself. 
Therefore, the H5N1 vaccines stockpiled in anticipation of a pandemic may lose efficacy 
and usefulness over time due to antigenic drift of circulating strains. Consequentially, it 
was suggested to use the stockpiled H5N1 vaccines to prime the population in this 
inter-pandemic period 
(http://www.who.int/immunization/sage/SAGE_H5N1_26Mayb.pdf). This priming can 
provide some protection against a potentially emerging pandemic. As we discussed 
above, there is a high probability of including adjuvants such as the oil-in-water emulsion 
MF59 in this pre-pandemic H5N1 vaccine priming. Therefore, it is essential to study the 
impact of adjuvants on 3 key criteria in order to be able to assess the potential usefulness 
of this priming:  
 
1) The generation of B-cell memory. 
2) The kinetics and magnitude of the recall response after the booster immunization. 
3) The breadth of the antibody response. 
 
As for the first two points, studies by Galli and colleagues have shown that 
priming with MF59 adjuvanted-H5N1 vaccines primed for a greater B-cell memory 
responses compared to plain vaccine primed or unprimed individuals (117). However, it 
is important to note that in this study the researchers estimated the memory responses by 
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examining the differences in recall responses after a booster immunization. Interestingly, 
the booster immunization vaccine was derived from clade 1 (A/Vietnam/1194/2004, 
H5N1) virus while the priming immunization vaccine was derived from a clade 0 
(A/duck/Singapore/1997, H5N3) virus i.e. heterologous prime-boost. In a similar study, 
Leroux-Roels and colleagues showed that another oil-in-water emulsion adjuvant, AS03, 
enhanced the initial priming effect of pre-pandemic H5N1 influenza vaccination enabling 
a rapid humoral response to single dose boosting with a heterologous strain (118). Both 
of the above mentioned clinical studies and others showed that priming with an oil-in-
water emulsion adjuvanted H5 antigen can result in a vastly improved response to 
subsequent vaccination, even if this subsequent vaccination is with a drifted strain (119). 
In contrast, at least in one of these studies, priming without adjuvant seemed to inhibit the 
response to subsequent vaccination with the heterologous strain (118). Moreover, 
including MF59, in multiple clinical trials with both seasonal and pandemic vaccines, 
enhanced antibody titers not only in response to homologous influenza strains but also to 
antigenically distinct virus strains (93, 94). Taken together, these results suggest that 
including the oil-in-water emulsion adjuvants with the pre-pandemic H5N1 vaccines 
increases the breadth of the responding B-cells. In line with this notion, Khurana et al. 
screened the binding of sera from participants in two separate clinical trials to linear 
epitopes spanning the length of HA and NA and observed that including MF59 adjuvant 
with H5N1 vaccines expanded the repertoire of responding antibodies (59). Our data 
contrast the proposed adjuvant-mediated “epitope spreading” of the responding 
antibodies by MF59-adjuvanted H5N1 vaccines. There are 2 key points that might 
explain this apparent discrepancy:  
 
1) The assay used to estimate the breadth of the antibody response. The vast 
majority of clinical studies utilize HI as a standard assay to evaluate vaccine 
mediated antibody responses in the sera of participants. The sensitivity of the 
assay may preclude the detection of the small proportion of antibodies 
reacting with the antigenically distinct variants in the generally weak 
responses elicited by unadjuvanted vaccines. 
 
2) Differences in the binding affinity of antibodies from the adjuvanted vs. the 
unadjuvanted vaccine responses. Our results showed that responding B-cells 
to the MF59-adjuvanted H5N1 vaccines experienced a greater degree of 
affinity maturation compared to B-cells activated by the unadjuvanted 
vaccine. While we did not directly assess the differences in binding affinities 
between these polyclonal responses, these differences, if existed, might 
contribute to the “epitope spreading” observed sera derived from individuals 
that received the MF59-adjuvanted vaccine. 
 
 
Future Directions  
 
One of the questions that remain unanswered is how adjuvants impact the 
diversity of the clonal B-cell responses. In the course of comparing the extent of affinity 
maturation of between adjuvanted and unadjuvanted B-cell responses, we sequenced the 
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immunoreceptor genes of activated B-cells. We believe that careful examination of these 
sequences would provide a preliminary insight regarding the clonal diversity within 
adjuvanted vs. unadjuvanted B-cell responses. Tiller and colleagues in a method report 
described the cloning and expression of murine Ig genes from single B cells (97). 
Performing a similar analysis on adjuvanted vs. unadjuvanted B-cell responses would not 
only allow for examining the clonal diversity of these responses but also their functional 
diversity as well. The latter would be defined by the differences in specificity and affinity 
of expressed immunoglobulins. 
 
 
Inflammasome-Independent Role of the Apoptosis-Associated Speck-Like Protein 
Containing CARD (ASC) in the Adjuvant Effect of MF59 
 
In Chapter 4, I investigated the possible roles of a key innate immune pathway, 
the NLRP3 inflammasome, in the adjuvanticity of the oil-in-water emulsion based 
adjuvant MF59 (120). We showed that, unlike the case for alum, MF59 does not require 
NLRP3 to exert its adjuvant effect. We showed that the H5-specific antibody response to 
MF59-adjuvanted H5N1 vaccine was not compromised in mice genetically deficient in 
NLRP3 and also in mice deficient in caspases-1, a key molecule in the NLRP3 
inflammasome. It was surprising, however, to see that the adapter molecule that bridges 
the interaction between NLRP3 and caspases-1, ASC, is indispensable for optimal 
MF59-mediated anti-H5 antibody response. Mice genetically deficient in ASC elicited 
significantly less anti-H5 HI and IgG titers compared to their wild type counterparts. 
These defects were not observed in the antibody response to the unadjuvanted vaccine or 
following sublethal H5N1 virus infection. Also the responses were intact when IFA and 
not MF59 was the adjuvant. We next showed that the decreased antibody titers are due to 
the failure of ASC-/- mice to develop a proper germinal center reaction in the draining 
lymph nodes following immunization. Finally, we showed that the production of the 
pro-inflammatory chemokines such as MIP-1b and MIP2 were decreased in BMDCs 
derived from ASC-/- compared to wild type cells upon treatment with MF59. 
 
 
Implications and Limitations 
 
 Similar to some commonly used vaccine adjuvants, the oil-in-water emulsion 
adjuvant MF59 functions via its ability to limit antigen dispersion from the injection site 
and consequentially promoting its uptake by professional APCs (60). This depot effect 
might be mediated by the oil component of the adjuvant. Another important aspect of the 
adjuvanticity of MF59 is the ability to trigger local inflammatory response that leads to 
the recruitment of various inflammatory cells to the injection site (104). The molecular 
mechanism underlying this immune stimulation is yet to be fully elucidated. In CFA, for 
example, the mineral oil component mediates the depot effect while the mycobacterial 
cell wall components would provide the ligands for the innate immune receptors.  
 
 The implication of the NLRP3 inflammasome in the immunostimulatory effect of 
alum has fueled the speculation of the role that this novel innate immune pathway might 
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be playing with other vaccine adjuvants (121). Indeed, in vitro studies revealed that 
particulate adjuvants such as the poly (lactic-co-glycolic acid) activated the NLRP3 
inflammasome as well (122). However, studies with mice that are genetically deficient in 
the cytosolic sensor NLRP3 showed minimal effect on the antibody responses stimulated 
by these adjuvants (65, 123). Our studies with MF59 clearly show that the NLRP3 
inflammasome is dispensable for the MF59-mediated immune stimulation. However, our 
data indicate that there is an inflammasome-independent pathway in which the adapter 
protein ASC is an essential component plays a vital role in the adjuvant effect of MF59. 
The promising nature of MF59 use in humans and the identification of ASC as a critical 
factor for the proper induction of the adaptive immune response to MF59-adjuvanted 
vaccines would have an important implications for the formulation of future influenza 
vaccines.  
 
 
Future Directions  
 
 Our knowledge of the innate immune system has expanded over the last decade 
(124). Currently there are no innate immune receptors directly implicated in the adjuvant 
effect of MF59 and other oil-in-water emulsion-based adjuvants (99). While our finding 
of the involvement of the adapter molecule ASC in the MF59 mechanism of action 
represents an important advancement in this regard, it will be essential to identify the 
upstream molecule or molecules that are also involved. Identifying these receptors will 
allow for the rational design of new vaccine adjuvants. 
 
 While our data indicate that ASC plays a role in the generation of the inflammatory 
response by innate immune cells in response to MF59 treatment. It will be important to 
determine the possible role of ASC within other immune cells such as B-cells and 
T-cells. Apart from that, the possible contribution of another major innate immune 
recognition system, the toll-like receptors (TLRs), in the adjuvant effect of MF59 has not 
been examined so far.  
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